[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Lidocaine.]
[J01GA01, streptomycin, The risk or severity of methemoglobinemia can be increased when Streptomycin is combined with Lidocaine.]
[L01AD04, streptozocin, The risk or severity of methemoglobinemia can be increased when Streptozocin is combined with Lidocaine.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Lidocaine.]
[J01CA16, sulbenicillin, The risk or severity of methemoglobinemia can be increased when Sulbenicillin is combined with Lidocaine.]
[S01AB04, sulfacetamide, The risk or severity of methemoglobinemia can be increased when Sulfacetamide is combined with Lidocaine.]
[J01EC02, sulfadiazine, The risk or severity of methemoglobinemia can be increased when Sulfadiazine is combined with Lidocaine.]
[J01ED07, sulfamerazine, The risk or severity of methemoglobinemia can be increased when Sulfamerazine is combined with Lidocaine.]
[J01EC01, sulfamethoxazole, The risk or severity of methemoglobinemia can be increased when Sulfamethoxazole is combined with Lidocaine.]
[J01ED05, sulfamethoxypyridazine, The risk or severity of methemoglobinemia can be increased when Sulfamethoxypyridazine is combined with Lidocaine.]
[J01EB06, sulfanilamide, The risk or severity of methemoglobinemia can be increased when Sulfanilamide is combined with Lidocaine.]
[J01EB04, sulfapyridine, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Sulfapyridine.]
[S01AB02, sulfisoxazole, The risk or severity of methemoglobinemia can be increased when Sulfisoxazole is combined with Lidocaine.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Lidocaine is combined with Sulpiride.]
[N03AX03, sulthiame, The risk or severity of methemoglobinemia can be increased when Sulthiame is combined with Lidocaine.]
[L01BB02, mercaptopurine, The risk or severity of methemoglobinemia can be increased when Mercaptopurine is combined with Lidocaine.]
[N06DA01, tacrine, The metabolism of Tacrine can be decreased when combined with Lidocaine.]
[J01CA15, talampicillin, The risk or severity of methemoglobinemia can be increased when Talampicillin is combined with Lidocaine.]
[L02BA01, tamoxifen, The risk or severity of methemoglobinemia can be increased when Tamoxifen is combined with Lidocaine.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Lidocaine.]
[L01CB02, teniposide, The risk or severity of methemoglobinemia can be increased when Teniposide is combined with Lidocaine.]
[G03BA03, testosterone, The metabolism of Testosterone can be decreased when combined with Lidocaine.]
[N07XX06, tetrabenazine, The metabolism of Tetrabenazine can be decreased when combined with Lidocaine.]
[S03AA02, tetracycline, The risk or severity of methemoglobinemia can be increased when Tetracycline is combined with Lidocaine.]
[J01DI02, ceftaroline fosamil, The risk or severity of methemoglobinemia can be increased when Ceftaroline fosamil is combined with Lidocaine.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Lidocaine is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Apomorphine.]
[L04AX02, thalidomide, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, The metabolism of Theobromine can be decreased when combined with Lidocaine.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Lidocaine.]
[P02CA02, thiabendazole, The metabolism of Thiabendazole can be decreased when combined with Lidocaine.]
[L01XX41, eribulin, The risk or severity of methemoglobinemia can be increased when Eribulin is combined with Lidocaine.]
[J01BA02, thiamphenicol, The risk or severity of methemoglobinemia can be increased when Thiamphenicol is combined with Lidocaine.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Thiethylperazine.]
[L01AC01, thiotepa, The risk or severity of methemoglobinemia can be increased when Thiotepa is combined with Lidocaine.]
[L01BB03, thioguanine, The risk or severity of methemoglobinemia can be increased when Tioguanine is combined with Lidocaine.]
[N05CA19, thiopental, The risk or severity of methemoglobinemia can be increased when Thiopental is combined with Lidocaine.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Thioproperazine.]
[N05AC02, thioridazine, The metabolism of Lidocaine can be decreased when combined with Thioridazine.]
[N05AF04, thiothixene, The metabolism of Thiothixene can be decreased when combined with Lidocaine.]
[C01BB04, aprindine, Lidocaine may increase the arrhythmogenic activities of Aprindine.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Lidocaine is combined with Tiapride.]
[J01CA13, ticarcillin, The risk or severity of methemoglobinemia can be increased when Ticarcillin is combined with Lidocaine.]
[B01AC05, ticlopidine, The metabolism of Lidocaine can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Tilidine.]
[S01ED01, timolol, The serum concentration of Lidocaine can be increased when it is combined with Timolol.]
[S01AA12, tobramycin, The risk or severity of methemoglobinemia can be increased when Tobramycin is combined with Lidocaine.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Lidocaine is combined with Tolperisone.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Lidocaine.]
[N06AF04, tranylcypromine, The metabolism of Lidocaine can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of adverse effects can be increased when Lidocaine is combined with Trazodone.]
[L01XF01, tretinoin, The risk or severity of methemoglobinemia can be increased when Tretinoin is combined with Lidocaine.]
[C03DB02, triamterene, The metabolism of Triamterene can be decreased when combined with Lidocaine.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Lidocaine is combined with Triazolam.]
[A03AB12, mepenzolate, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, The metabolism of Trifluoperazine can be decreased when combined with Lidocaine.]
[S01AD02, trifluridine, The risk or severity of methemoglobinemia can be increased when Trifluridine is combined with Lidocaine.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Lidocaine is combined with Trifluperidol.]
[N05AA05, triflupromazine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[R03BA07, mometasone, The metabolism of Lidocaine can be increased when combined with Mometasone.]
[A03AA05, trimebutine, Lidocaine may increase the arrhythmogenic activities of Trimebutine.]
[S01ED04, metipranolol, Lidocaine may increase the arrhythmogenic activities of Metipranolol.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Alimemazine.]
[N03AC02, trimethadione, Lidocaine may increase the arrhythmogenic activities of Trimethadione.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Lidocaine.]
[R06AC04, tripelennamine, The metabolism of Lidocaine can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Triprolidine.]
[A03BB01, butylscopolamine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Lidocaine can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Lidocaine can be decreased when combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Lidocaine.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Tubocurarine.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Lidocaine.]
[L01FX04, ipilimumab, The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Lidocaine.]
[L01EX04, vandetanib, The risk or severity of methemoglobinemia can be increased when Vandetanib is combined with Lidocaine.]
[L01AD08, uracil mustard, The risk or severity of methemoglobinemia can be increased when Uracil mustard is combined with Lidocaine.]
[L02BX03, abiraterone, The serum concentration of Lidocaine can be increased when it is combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Lidocaine can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Lidocaine can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Lidocaine can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Lidocaine can be decreased when combined with Rilpivirine.]
[A07AA12, fidaxomicin, The risk or severity of methemoglobinemia can be increased when Fidaxomicin is combined with Lidocaine.]
[S01AA28, vancomycin, The risk or severity of methemoglobinemia can be increased when Vancomycin is combined with Lidocaine.]
[N03AX21, ezogabine, The risk or severity of methemoglobinemia can be increased when Ezogabine is combined with Lidocaine.]
[B01AF01, rivaroxaban, The metabolism of Rivaroxaban can be decreased when combined with Lidocaine.]
[B01AC24, ticagrelor, The metabolism of Ticagrelor can be decreased when combined with Lidocaine.]
[C08DA01, verapamil, Lidocaine may increase the arrhythmogenic activities of Verapamil.]
[N06AX09, viloxazine, The metabolism of Lidocaine can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The risk or severity of methemoglobinemia can be increased when Vinblastine is combined with Lidocaine.]
[C04AX07, vincamine, The risk or severity of methemoglobinemia can be increased when Vincamine is combined with Lidocaine.]
[L01CA02, vincristine, The risk or severity of methemoglobinemia can be increased when Vincristine is combined with Lidocaine.]
[L01CA03, vindesine, The risk or severity of methemoglobinemia can be increased when Vindesine is combined with Lidocaine.]
[B01AA03, warfarin, The metabolism of Warfarin can be decreased when combined with Lidocaine.]
[S01AA13, fusidic acid, The metabolism of Lidocaine can be decreased when combined with Fusidic acid.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Lidocaine is combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Lidocaine can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of methemoglobinemia can be increased when Levetiracetam is combined with Lidocaine.]
[L01EC01, vemurafenib, The serum concentration of Lidocaine can be increased when it is combined with Vemurafenib.]
[M05BA03, pamidronic acid, The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Lidocaine.]
[L01FX05, brentuximab vedotin, The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Lidocaine.]
[L01ED01, crizotinib, The risk or severity of methemoglobinemia can be increased when Crizotinib is combined with Lidocaine.]
[L01XD05, temoporfin, The risk or severity of methemoglobinemia can be increased when Temoporfin is combined with Lidocaine.]
[J01MA13, trovafloxacin, The risk or severity of methemoglobinemia can be increased when Trovafloxacin is combined with Lidocaine.]
[L01XX02, asparaginase, The risk or severity of methemoglobinemia can be increased when Asparaginase Escherichia coli is combined with Lidocaine.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Lidocaine is combined with Ziprasidone.]
[L04AA34, alemtuzumab, The risk or severity of methemoglobinemia can be increased when Alemtuzumab is combined with Lidocaine.]
[L01EJ01, ruxolitinib, The risk or severity of methemoglobinemia can be increased when Ruxolitinib is combined with Lidocaine.]
[G04BD07, tolterodine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[J01DH04, doripenem, The risk or severity of methemoglobinemia can be increased when Doripenem is combined with Lidocaine.]
[C07AB03, atenolol, The serum concentration of Lidocaine can be increased when it is combined with Atenolol.]
[L03AB11, peginterferon alfa-2a, The risk or severity of methemoglobinemia can be increased when Peginterferon alfa-2a is combined with Lidocaine.]
[L01FA01, rituximab, The risk or severity of methemoglobinemia can be increased when Rituximab is combined with Lidocaine.]
[J02AC03, voriconazole, The metabolism of Lidocaine can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Lidocaine is combined with Atracurium.]
[S01FA01, atropine, Lidocaine may increase the arrhythmogenic activities of Atropine.]
[L01XJ01, vismodegib, The risk or severity of methemoglobinemia can be increased when Vismodegib is combined with Lidocaine.]
[L01EK01, axitinib, The risk or severity of methemoglobinemia can be increased when Axitinib is combined with Lidocaine.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be decreased when combined with Lidocaine.]
[H02AB11, prednylidene, The metabolism of Lidocaine can be increased when combined with Prednylidene.]
[L01BC07, azacitidine, The risk or severity of methemoglobinemia can be increased when Azacitidine is combined with Lidocaine.]
[L04AX01, azathioprine, The metabolism of Azathioprine can be decreased when combined with Lidocaine.]
[L01BC05, gemcitabine, The risk or severity of methemoglobinemia can be increased when Gemcitabine is combined with Lidocaine.]
[J01CA09, azlocillin, The risk or severity of methemoglobinemia can be increased when Azlocillin is combined with Lidocaine.]
[J01DF01, aztreonam, The risk or severity of methemoglobinemia can be increased when Aztreonam is combined with Lidocaine.]
[R02AB04, bacitracin, The risk or severity of methemoglobinemia can be increased when Bacitracin is combined with Lidocaine.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Lidocaine.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of methemoglobinemia can be increased when Gemtuzumab ozogamicin is combined with Lidocaine.]
[L01FD02, pertuzumab, The risk or severity of methemoglobinemia can be increased when Pertuzumab is combined with Lidocaine.]
[A08AA11, lorcaserin, The metabolism of Lidocaine can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Lidocaine can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, The risk or severity of methemoglobinemia can be increased when Carfilzomib is combined with Lidocaine.]
[V03AX03, cobicistat, The metabolism of Lidocaine can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Lidocaine can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Lidocaine can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The risk or severity of methemoglobinemia can be increased when Bosutinib is combined with Lidocaine.]
[L04AA31, teriflunomide, The serum concentration of Lidocaine can be decreased when it is combined with Teriflunomide.]
[C01CA18, octopamine, The risk or severity of hypertension can be increased when Octopamine is combined with Lidocaine.]
[L01EX05, regorafenib, The risk or severity of methemoglobinemia can be increased when Regorafenib is combined with Lidocaine.]
[L01XL02, talimogene laherparepvec, The risk or severity of methemoglobinemia can be increased when Talimogene laherparepvec is combined with Lidocaine.]
[N05CA04, barbital, The risk or severity of methemoglobinemia can be increased when Barbital is combined with Lidocaine.]
[C01AA01, acetyldigitoxin, Lidocaine may increase the arrhythmogenic activities of Acetyldigitoxin.]
[J05AE04, nelfinavir, The metabolism of Lidocaine can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The risk or severity of methemoglobinemia can be increased when Bendamustine is combined with Lidocaine.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.]
[N04BD02, rasagiline, The metabolism of Rasagiline can be decreased when combined with Lidocaine.]
[C08CA13, lercanidipine, Lidocaine may increase the arrhythmogenic activities of Lercanidipine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Lidocaine is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Lidocaine is combined with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.]
[N02CC03, zolmitriptan, The metabolism of Zolmitriptan can be decreased when combined with Lidocaine.]
[R06AC06, thonzylamine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, The metabolism of Lidocaine can be decreased when combined with Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Lidocaine is combined with Diethyl ether.]
[L01EX07, cabozantinib, The risk or severity of methemoglobinemia can be increased when Cabozantinib is combined with Lidocaine.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be decreased when combined with Lidocaine.]
[L01EA05, ponatinib, The risk or severity of methemoglobinemia can be increased when Ponatinib is combined with Lidocaine.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Lidocaine.]
[J04AK05, bedaquiline, The risk or severity of methemoglobinemia can be increased when Bedaquiline is combined with Lidocaine.]
[C04AX11, bencyclane, Lidocaine may increase the arrhythmogenic activities of Bencyclane.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Lidocaine.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Lidocaine can be decreased when combined with Glycerol phenylbutyrate.]
[L04AX06, pomalidomide, The risk or severity of methemoglobinemia can be increased when Pomalidomide is combined with Lidocaine.]
[G03XC05, ospemifene, The metabolism of Lidocaine can be decreased when combined with Ospemifene.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Lidocaine is combined with Benperidol.]
[J01MA15, gemifloxacin, The risk or severity of methemoglobinemia can be increased when Gemifloxacin is combined with Lidocaine.]
[S01AE07, moxifloxacin, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Lidocaine.]
[A06AX06, tegaserod, The metabolism of Lidocaine can be decreased when combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Benzocaine.]
[M01AH01, celecoxib, The metabolism of Lidocaine can be decreased when combined with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of hypertension can be increased when Naratriptan is combined with Lidocaine.]
[L04AA18, everolimus, The risk or severity of methemoglobinemia can be increased when Everolimus is combined with Lidocaine.]
[N04AC01, benztropine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Lidocaine can be decreased when it is combined with Dabrafenib.]
[L01EE01, trametinib, The risk or severity of methemoglobinemia can be increased when Trametinib is combined with Lidocaine.]
[L01EB03, afatinib, The risk or severity of methemoglobinemia can be increased when Afatinib is combined with Lidocaine.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Lidocaine is combined with Levomilnacipran.]
[C08EA02, bepridil, Lidocaine may increase the arrhythmogenic activities of Bepridil.]
[L01EL01, ibrutinib, The risk or severity of methemoglobinemia can be increased when Ibrutinib is combined with Lidocaine.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Vortioxetine.]
[N03AF04, eslicarbazepine, The risk or severity of methemoglobinemia can be increased when Eslicarbazepine is combined with Lidocaine.]
[J05AP05, simeprevir, The metabolism of Lidocaine can be decreased when combined with Simeprevir.]
[N03AG04, vigabatrin, The risk or severity of methemoglobinemia can be increased when Vigabatrin is combined with Lidocaine.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Lidocaine.]
[C07AB04, acebutolol, The serum concentration of Lidocaine can be increased when it is combined with Acebutolol.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be decreased when combined with Lidocaine.]
[A16AA07, metreleptin, The metabolism of Lidocaine can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Lidocaine can be increased when combined with Apremilast.]
[P01CX04, miltefosine, The risk or severity of methemoglobinemia can be increased when Miltefosine is combined with Lidocaine.]
[L02BG02, formestane, The risk or severity of methemoglobinemia can be increased when Formestane is combined with Lidocaine.]
[S03BA03, betamethasone, The metabolism of Lidocaine can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, The serum concentration of Lidocaine can be increased when it is combined with Betaxolol.]
[L04AC11, siltuximab, The metabolism of Lidocaine can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The risk or severity of methemoglobinemia can be increased when Ceritinib is combined with Lidocaine.]
[L01FG02, ramucirumab, The risk or severity of methemoglobinemia can be increased when Ramucirumab is combined with Lidocaine.]
[J01XA04, dalbavancin, The risk or severity of methemoglobinemia can be increased when Dalbavancin is combined with Lidocaine.]
[A03BA03, hyoscyamine, Lidocaine may increase the arrhythmogenic activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be decreased when combined with Lidocaine.]
[J01XX11, tedizolid, The risk or severity of methemoglobinemia can be increased when Tedizolid is combined with Lidocaine.]
[L01XH04, belinostat, The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Lidocaine.]
[L01EM01, idelalisib, The risk or severity of methemoglobinemia can be increased when Idelalisib is combined with Lidocaine.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Lidocaine is combined with Alfaxalone.]
[D11AA01, glycopyrronium, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The metabolism of Lidocaine can be decreased when combined with Eliglustat.]
[L01FF02, pembrolizumab, The risk or severity of methemoglobinemia can be increased when Pembrolizumab is combined with Lidocaine.]
[J01XA05, oritavancin, The risk or severity of methemoglobinemia can be increased when Oritavancin is combined with Lidocaine.]
[S01AA15, dihydrostreptomycin, The risk or severity of methemoglobinemia can be increased when Dihydrostreptomycin is combined with Lidocaine.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Acepromazine.]
[L01BC08, decitabine, The risk or severity of methemoglobinemia can be increased when Decitabine is combined with Lidocaine.]
[N04AA02, biperiden, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Lidocaine.]
[L01EX09, nintedanib, The risk or severity of methemoglobinemia can be increased when Nintedanib is combined with Lidocaine.]
[S03AA06, gentamicin, The risk or severity of methemoglobinemia can be increased when Gentamicin is combined with Lidocaine.]
[L01FX07, blinatumomab, The risk or severity of methemoglobinemia can be increased when Blinatumomab is combined with Lidocaine.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Lidocaine.]
[L01XK01, olaparib, The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Lidocaine.]
[L01FF01, nivolumab, The risk or severity of methemoglobinemia can be increased when Nivolumab is combined with Lidocaine.]
[N06AX11, mirtazapine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Lidocaine can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The risk or severity of methemoglobinemia can be increased when Palbociclib is combined with Lidocaine.]
[L01EX08, lenvatinib, The risk or severity of methemoglobinemia can be increased when Lenvatinib is combined with Lidocaine.]
[L01XH03, panobinostat, The metabolism of Lidocaine can be decreased when combined with Panobinostat.]
[J05AP07, daclatasvir, The metabolism of Daclatasvir can be decreased when combined with Lidocaine.]
[N02BE01, acetaminophen, The risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Lidocaine.]
[L01DC01, bleomycin, The risk or severity of methemoglobinemia can be increased when Bleomycin is combined with Lidocaine.]
[A03AA09, difemerine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[J05AP06, asunaprevir, The metabolism of Lidocaine can be decreased when combined with Asunaprevir.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Lidocaine is combined with Brexpiprazole.]
[L01XJ02, sonidegib, The risk or severity of methemoglobinemia can be increased when Sonidegib is combined with Lidocaine.]
[A04AD14, rolapitant, The metabolism of Lidocaine can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Lidocaine is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Cariprazine.]
[S01EC01, acetazolamide, The risk or severity of methemoglobinemia can be increased when Acetazolamide is combined with Lidocaine.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Acetophenazine.]
[S02AA10, acetic acid, The risk or severity of methemoglobinemia can be increased when Acetic acid is combined with Lidocaine.]
[B02BC05, adrenalone, The risk or severity of hypertension can be increased when Adrenalone is combined with Lidocaine.]
[A02BC03, lansoprazole, The metabolism of Lidocaine can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The risk or severity of methemoglobinemia can be increased when Trabectedin is combined with Lidocaine.]
[J02AC05, isavuconazole, The metabolism of Lidocaine can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Lidocaine can be decreased when it is combined with Osimertinib.]
[L01FC01, daratumumab, The risk or severity of methemoglobinemia can be increased when Daratumumab is combined with Lidocaine.]
[L01EE02, cobimetinib, The risk or severity of methemoglobinemia can be increased when Cobimetinib is combined with Lidocaine.]
[L01XG03, ixazomib, The risk or severity of methemoglobinemia can be increased when Ixazomib is combined with Lidocaine.]
[L01FE03, necitumumab, The risk or severity of methemoglobinemia can be increased when Necitumumab is combined with Lidocaine.]
[L01FX08, elotuzumab, The risk or severity of methemoglobinemia can be increased when Elotuzumab is combined with Lidocaine.]
[L01ED03, alectinib, The risk or severity of methemoglobinemia can be increased when Alectinib is combined with Lidocaine.]
[L01XA04, satraplatin, The risk or severity of methemoglobinemia can be increased when Satraplatin is combined with Lidocaine.]
[J05AP10, elbasvir, The metabolism of Elbasvir can be decreased when combined with Lidocaine.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Lidocaine is combined with Aprobarbital.]
[N03AX23, brivaracetam, The risk or severity of methemoglobinemia can be increased when Brivaracetam is combined with Lidocaine.]
[L01XX52, venetoclax, The risk or severity of methemoglobinemia can be increased when Venetoclax is combined with Lidocaine.]
[N05BA08, bromazepam, The metabolism of Bromazepam can be decreased when combined with Lidocaine.]
[N04BC01, bromocriptine, The risk or severity of hypertension can be increased when Bromocriptine is combined with Lidocaine.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Alverine.]
[R06AB01, brompheniramine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Lidocaine is combined with Amineptine.]
[C08CA01, amlodipine, Lidocaine may increase the arrhythmogenic activities of Amlodipine.]
[L01FF05, atezolizumab, The risk or severity of methemoglobinemia can be increased when Atezolizumab is combined with Lidocaine.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Lidocaine is combined with Aniracetam.]
[A05AA04, obeticholic acid, The metabolism of Lidocaine can be decreased when combined with Obeticholic acid.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Levobupivacaine.]
[C07AA19, bupranolol, The serum concentration of Lidocaine can be increased when it is combined with Bupranolol.]
[N07BC01, buprenorphine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02AE01, buserelin, The risk or severity of methemoglobinemia can be increased when Buserelin is combined with Lidocaine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Lidocaine is combined with Buspirone.]
[L01AB01, busulfan, The risk or severity of methemoglobinemia can be increased when Busulfan is combined with Lidocaine.]
[L01XX27, arsenic trioxide, The risk or severity of methemoglobinemia can be increased when Arsenic trioxide is combined with Lidocaine.]
[P01BE02, artemether, The risk or severity of methemoglobinemia can be increased when Artemether is combined with Lidocaine.]
[P01BE03, artesunate, The risk or severity of methemoglobinemia can be increased when Artesunate is combined with Lidocaine.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Lidocaine is combined with Butorphanol.]
[J01MA09, sparfloxacin, The risk or severity of methemoglobinemia can be increased when Sparfloxacin is combined with Lidocaine.]
[L01FX10, olaratumab, The risk or severity of methemoglobinemia can be increased when Olaratumab is combined with Lidocaine.]
[S01GX07, azelastine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[J01CE04, azidocillin, The risk or severity of methemoglobinemia can be increased when Azidocillin is combined with Lidocaine.]
[L01XK03, rucaparib, The metabolism of Lidocaine can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of methemoglobinemia can be increased when Azithromycin is combined with Lidocaine.]
[J01CA06, bacampicillin, The risk or severity of methemoglobinemia can be increased when Bacampicillin is combined with Lidocaine.]
[L01EF02, ribociclib, The metabolism of Lidocaine can be decreased when combined with Ribociclib.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Lidocaine.]
[L01FF04, avelumab, The risk or severity of methemoglobinemia can be increased when Avelumab is combined with Lidocaine.]
[N07XX16, deutetrabenazine, The metabolism of Deutetrabenazine can be decreased when combined with Lidocaine.]
[N02BF02, pregabalin, The therapeutic efficacy of Lidocaine can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of methemoglobinemia can be increased when Beclamide is combined with Lidocaine.]
[N06BC01, caffeine, The metabolism of Lidocaine can be decreased when combined with Caffeine.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Oxybuprocaine.]
[J01XX08, linezolid, The risk or severity of methemoglobinemia can be increased when Linezolid is combined with Lidocaine.]
[J05AE09, tipranavir, The metabolism of Lidocaine can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Lidocaine.]
[L01XK02, niraparib, The risk or severity of methemoglobinemia can be increased when Niraparib is combined with Lidocaine.]
[L04AB02, infliximab, The metabolism of Lidocaine can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Lidocaine can be decreased when combined with Midostaurin.]
[L01FF03, durvalumab, The risk or severity of methemoglobinemia can be increased when Durvalumab is combined with Lidocaine.]
[L01ED04, brigatinib, The risk or severity of methemoglobinemia can be increased when Brigatinib is combined with Lidocaine.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Lidocaine is combined with Safinamide.]
[P01AX10, fumagillin, The risk or severity of methemoglobinemia can be increased when Fumagillin is combined with Lidocaine.]
[J01MA23, delafloxacin, The risk or severity of methemoglobinemia can be increased when Delafloxacin is combined with Lidocaine.]
[P03AC02, bioallethrin, Lidocaine may increase the arrhythmogenic activities of Bioallethrin.]
[L01BC06, capecitabine, The risk or severity of methemoglobinemia can be increased when Capecitabine is combined with Lidocaine.]
[L01XX59, enasidenib, The risk or severity of methemoglobinemia can be increased when Enasidenib is combined with Lidocaine.]
[L01EH02, neratinib, The risk or severity of methemoglobinemia can be increased when Neratinib is combined with Lidocaine.]
[L01FB01, inotuzumab ozogamicin, The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Lidocaine.]
[L01XH01, vorinostat, The risk or severity of methemoglobinemia can be increased when Vorinostat is combined with Lidocaine.]
[L01EM02, copanlisib, The risk or severity of methemoglobinemia can be increased when Copanlisib is combined with Lidocaine.]
[L01EF03, abemaciclib, The risk or severity of methemoglobinemia can be increased when Abemaciclib is combined with Lidocaine.]
[C07AB07, bisoprolol, The serum concentration of Lidocaine can be increased when it is combined with Bisoprolol.]
[J05AG03, efavirenz, The metabolism of Lidocaine can be decreased when combined with Efavirenz.]
[J01DC10, cefprozil, The risk or severity of methemoglobinemia can be increased when Cefprozil is combined with Lidocaine.]
[C07AA17, bopindolol, The serum concentration of Lidocaine can be increased when it is combined with Bopindolol.]
[N04AA11, bornaprine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[L01BA03, raltitrexed, The risk or severity of methemoglobinemia can be increased when Raltitrexed is combined with Lidocaine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Lidocaine is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Lidocaine is combined with Brotizolam.]
[R03BA02, budesonide, The metabolism of Lidocaine can be increased when combined with Budesonide.]
[L01XL04, tisagenlecleucel, The risk or severity of methemoglobinemia can be increased when Tisagenlecleucel is combined with Lidocaine.]
[L01EL02, acalabrutinib, The metabolism of Lidocaine can be decreased when combined with Acalabrutinib.]
[L01XL03, axicabtagene ciloleucel, The risk or severity of methemoglobinemia can be increased when Axicabtagene ciloleucel is combined with Lidocaine.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Lidocaine is combined with Butobarbital.]
[J05AX18, letermovir, The metabolism of Lidocaine can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Lidocaine is combined with Butriptyline.]
[C01AA02, acetyldigoxins, Lidocaine may increase the arrhythmogenic activities of Acetyldigoxin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Lidocaine is combined with Vinylbital.]
[C01CX09, angiotensin II, The risk or severity of hypertension can be increased when Angiotensin II is combined with Lidocaine.]
[L02BB05, apalutamide, The risk or severity of methemoglobinemia can be increased when Apalutamide is combined with Lidocaine.]
[N03AF01, carbamazepine, The risk or severity of methemoglobinemia can be increased when Carbamazepine is combined with Lidocaine.]
[A03AA03, camylofine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[J01CA03, carbenicillin, The risk or severity of methemoglobinemia can be increased when Carbenicillin is combined with Lidocaine.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Carbinoxamine.]
[L03AB06, interferon alfa-n1, The metabolism of Lidocaine can be decreased when combined with Interferon alfa-n1.]
[C07AG02, carvedilol, The serum concentration of Lidocaine can be increased when it is combined with Carvedilol.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Lidocaine.]
[J01DE01, cefepime, The risk or severity of methemoglobinemia can be increased when Cefepime is combined with Lidocaine.]
[J01DD10, cefetamet, The risk or severity of methemoglobinemia can be increased when Cefetamet is combined with Lidocaine.]
[J01DD09, cefodizime, The risk or severity of methemoglobinemia can be increased when Cefodizime is combined with Lidocaine.]
[J01DC11, ceforanide, The risk or severity of methemoglobinemia can be increased when Ceforanide is combined with Lidocaine.]
[J01DD13, cefpodoxime, The risk or severity of methemoglobinemia can be increased when Cefpodoxime is combined with Lidocaine.]
[L01EC03, encorafenib, The risk or severity of methemoglobinemia can be increased when Encorafenib is combined with Lidocaine.]
[L01EE03, binimetinib, The risk or severity of methemoglobinemia can be increased when Binimetinib is combined with Lidocaine.]
[J01DD14, ceftibuten, The risk or severity of methemoglobinemia can be increased when Ceftibuten is combined with Lidocaine.]
[J01GB14, plazomicin, The risk or severity of methemoglobinemia can be increased when Plazomicin is combined with Lidocaine.]
[C07AB08, celiprolol, The serum concentration of Lidocaine can be increased when it is combined with Celiprolol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Lidocaine.]
[L01XX62, ivosidenib, The metabolism of Lidocaine can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The risk or severity of methemoglobinemia can be increased when Tafenoquine is combined with Lidocaine.]
[L01FX09, mogamulizumab, The risk or severity of methemoglobinemia can be increased when Mogamulizumab is combined with Lidocaine.]
[N03AX17, stiripentol, The metabolism of Lidocaine can be decreased when combined with Stiripentol.]
[J05AG06, doravirine, The metabolism of Doravirine can be decreased when combined with Lidocaine.]
[J01AA13, eravacycline, The risk or severity of methemoglobinemia can be increased when Eravacycline is combined with Lidocaine.]
[L01EM04, duvelisib, The risk or severity of methemoglobinemia can be increased when Duvelisib is combined with Lidocaine.]
[L01FF06, cemiplimab, The risk or severity of methemoglobinemia can be increased when Cemiplimab is combined with Lidocaine.]
[L01EB07, dacomitinib, The risk or severity of methemoglobinemia can be increased when Dacomitinib is combined with Lidocaine.]
[J01AA14, sarecycline, The risk or severity of methemoglobinemia can be increased when Sarecycline is combined with Lidocaine.]
[J01AA15, omadacycline, The risk or severity of methemoglobinemia can be increased when Omadacycline is combined with Lidocaine.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Cetirizine.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Lidocaine is combined with Carbromal.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be decreased when combined with Lidocaine.]
[L01FB02, moxetumomab pasudotox, The risk or severity of methemoglobinemia can be increased when Moxetumomab pasudotox is combined with Lidocaine.]
[L01XK04, talazoparib, The risk or severity of methemoglobinemia can be increased when Talazoparib is combined with Lidocaine.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Lidocaine.]
[R03BB08, revefenacin, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01ED05, lorlatinib, The risk or severity of methemoglobinemia can be increased when Lorlatinib is combined with Lidocaine.]
[L04AA39, emapalumab, The metabolism of Lidocaine can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of methemoglobinemia can be increased when Carmustine is combined with Lidocaine.]
[L01EX12, larotrectinib, The risk or severity of methemoglobinemia can be increased when Larotrectinib is combined with Lidocaine.]
[L01EX13, gilteritinib, The risk or severity of methemoglobinemia can be increased when Gilteritinib is combined with Lidocaine.]
[L01XJ03, glasdegib, The risk or severity of methemoglobinemia can be increased when Glasdegib is combined with Lidocaine.]
[N07XX05, amifampridine, The risk or severity of seizure can be increased when Lidocaine is combined with Amifampridine.]
[L01XX67, tagraxofusp, The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Lidocaine.]
[C01BG07, cifenline, Lidocaine may increase the arrhythmogenic activities of Cibenzoline.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Lidocaine.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Lidocaine is combined with Cinitapride.]
[S01ED05, carteolol, Lidocaine may increase the arrhythmogenic activities of Carteolol.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be decreased when combined with Lidocaine.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Esketamine.]
[J01FA09, clarithromycin, The metabolism of Lidocaine can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Lidocaine is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of methemoglobinemia can be increased when Brexanolone is combined with Lidocaine.]
[L01EN01, erdafitinib, The risk or severity of methemoglobinemia can be increased when Erdafitinib is combined with Lidocaine.]
[N05BA09, clobazam, The metabolism of Lidocaine can be decreased when combined with Clobazam.]
[J01AA11, clomocycline, The risk or severity of methemoglobinemia can be increased when Clomocycline is combined with Lidocaine.]
[H02AB14, cloprednol, The metabolism of Lidocaine can be increased when combined with Cloprednol.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Lidocaine is combined with Cloxazolam.]
[L01XX29, denileukin diftitox, The risk or severity of methemoglobinemia can be increased when Denileukin diftitox is combined with Lidocaine.]
[L04AB01, etanercept, The metabolism of Lidocaine can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Lidocaine can be increased when combined with Cortivazol.]
[L01EM03, alpelisib, The risk or severity of methemoglobinemia can be increased when Alpelisib is combined with Lidocaine.]
[L01FX14, polatuzumab vedotin, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Lidocaine.]
[J01DC04, cefaclor, The risk or severity of methemoglobinemia can be increased when Cefaclor is combined with Lidocaine.]
[J01DB05, cefadroxil, The risk or severity of methemoglobinemia can be increased when Cefadroxil is combined with Lidocaine.]
[J01DC03, cefamandole, The risk or severity of methemoglobinemia can be increased when Cefamandole is combined with Lidocaine.]
[L01XX66, selinexor, The risk or severity of methemoglobinemia can be increased when Selinexor is combined with Lidocaine.]
[J01DB07, cefatrizine, The risk or severity of methemoglobinemia can be increased when Cefatrizine is combined with Lidocaine.]
[L02BB06, darolutamide, The risk or severity of methemoglobinemia can be increased when Darolutamide is combined with Lidocaine.]
[J01CF03, methicillin, The risk or severity of methemoglobinemia can be increased when Meticillin is combined with Lidocaine.]
[J01DC09, cefmetazole, The risk or severity of methemoglobinemia can be increased when Cefmetazole is combined with Lidocaine.]
[J01DC06, cefonicid, The risk or severity of methemoglobinemia can be increased when Cefonicid is combined with Lidocaine.]
[L01EX15, pexidartinib, The risk or severity of methemoglobinemia can be increased when Pexidartinib is combined with Lidocaine.]
[J01DD12, cefoperazone, The risk or severity of methemoglobinemia can be increased when Cefoperazone is combined with Lidocaine.]
[J01DC05, cefotetan, The risk or severity of methemoglobinemia can be increased when Cefotetan is combined with Lidocaine.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Cyamemazine.]
[J01DC07, cefotiam, The risk or severity of methemoglobinemia can be increased when Cefotiam is combined with Lidocaine.]
[J01DC01, cefoxitin, The risk or severity of methemoglobinemia can be increased when Cefoxitin is combined with Lidocaine.]
[J01DD03, cefsulodin, The risk or severity of methemoglobinemia can be increased when Cefsulodin is combined with Lidocaine.]
[J01DD02, ceftazidime, The risk or severity of methemoglobinemia can be increased when Ceftazidime is combined with Lidocaine.]
[C03BX03, cicletanine, Lidocaine may increase the arrhythmogenic activities of Cicletanine.]
[J01DD07, ceftizoxime, The risk or severity of methemoglobinemia can be increased when Ceftizoxime is combined with Lidocaine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Lidocaine.]
[L01EJ02, fedratinib, The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Lidocaine.]
[L01EX14, entrectinib, The risk or severity of methemoglobinemia can be increased when Entrectinib is combined with Lidocaine.]
[N07XX11, pitolisant, The serum concentration of Lidocaine can be decreased when it is combined with Pitolisant.]
[J01XX12, lefamulin, The risk or severity of methemoglobinemia can be increased when Lefamulin is combined with Lidocaine.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Lidocaine.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Yohimbine.]
[A10AE03, insulin, regular, pork, The metabolism of Lidocaine can be increased when combined with Insulin pork.]
[J01XX09, daptomycin, The risk or severity of methemoglobinemia can be increased when Daptomycin is combined with Lidocaine.]
[J01DB01, cephalexin, The risk or severity of methemoglobinemia can be increased when Cephalexin is combined with Lidocaine.]
[J01DB02, cephaloridine, The risk or severity of methemoglobinemia can be increased when Cefaloridine is combined with Lidocaine.]
[J01DB03, cephalothin, The risk or severity of methemoglobinemia can be increased when Cefalotin is combined with Lidocaine.]
[J01DB08, cephapirin, The risk or severity of methemoglobinemia can be increased when Cefapirin is combined with Lidocaine.]
[J01DB09, cephradine, The risk or severity of methemoglobinemia can be increased when Cefradine is combined with Lidocaine.]
[L01FD01, trastuzumab, The risk or severity of methemoglobinemia can be increased when Trastuzumab is combined with Lidocaine.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of methemoglobinemia can be increased when Trastuzumab emtansine is combined with Lidocaine.]
[L01FD04, trastuzumab deruxtecan, The risk or severity of methemoglobinemia can be increased when Trastuzumab deruxtecan is combined with Lidocaine.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Lidocaine.]
[L01EL03, zanubrutinib, The risk or severity of methemoglobinemia can be increased when Zanubrutinib is combined with Lidocaine.]
[N03AX25, cenobamate, The serum concentration of Lidocaine can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Lidocaine can be increased when it is combined with Givosiran.]
[L01FX13, enfortumab vedotin, The risk or severity of methemoglobinemia can be increased when Enfortumab vedotin is combined with Lidocaine.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Dexbrompheniramine.]
[R06AB02, dexchlorpheniramine, The metabolism of Dexchlorpheniramine can be decreased when combined with Lidocaine.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Dezocine.]
[L01XX10, masoprocol, The risk or severity of methemoglobinemia can be increased when Masoprocol is combined with Lidocaine.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Lidocaine is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Lidocaine is combined with Lumateperone.]
[M01AX21, diacetylrhein, The metabolism of Lidocaine can be decreased when combined with Diacerein.]
[L01FC02, isatuximab, The risk or severity of methemoglobinemia can be increased when Isatuximab is combined with Lidocaine.]
[S01AE06, gatifloxacin, The risk or severity of methemoglobinemia can be increased when Gatifloxacin is combined with Lidocaine.]
[H02CA02, osilodrostat, The metabolism of Lidocaine can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Lidocaine can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The metabolism of Frovatriptan can be decreased when combined with Lidocaine.]
[G04CB02, dutasteride, The metabolism of Dutasteride can be decreased when combined with Lidocaine.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Lidocaine is combined with Dichloralphenazone.]
[L01EE04, selumetinib, The risk or severity of methemoglobinemia can be increased when Selumetinib is combined with Lidocaine.]
[G03DB08, dienogest, The risk or severity of methemoglobinemia can be increased when Dienogest is combined with Lidocaine.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Lidocaine is combined with Difenoxin.]
[L01XD01, porfimer sodium, The risk or severity of methemoglobinemia can be increased when Porfimer sodium is combined with Lidocaine.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Lidocaine.]
[M01AH02, rofecoxib, The metabolism of Lidocaine can be decreased when combined with Rofecoxib.]
[L01XF03, bexarotene, The risk or severity of methemoglobinemia can be increased when Bexarotene is combined with Lidocaine.]
[C08CA16, clevidipine, Lidocaine may increase the arrhythmogenic activities of Clevidipine.]
[C01BD07, dronedarone, The metabolism of Lidocaine can be decreased when combined with Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of methemoglobinemia can be increased when Valpromide is combined with Lidocaine.]
[J01FA13, dirithromycin, The risk or severity of methemoglobinemia can be increased when Dirithromycin is combined with Lidocaine.]
[L01AA02, chlorambucil, The risk or severity of methemoglobinemia can be increased when Chlorambucil is combined with Lidocaine.]
[S03AA08, chloramphenicol, The risk or severity of methemoglobinemia can be increased when Chloramphenicol is combined with Lidocaine.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Lidocaine is combined with Chlordiazepoxide.]
[L01EN02, pemigatinib, The risk or severity of methemoglobinemia can be increased when Pemigatinib is combined with Lidocaine.]
[L01FX17, sacituzumab govitecan, The risk or severity of methemoglobinemia can be increased when Sacituzumab govitecan is combined with Lidocaine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Lidocaine.]
[A03AA08, dihexyverine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[L01EX17, capmatinib, The risk or severity of methemoglobinemia can be increased when Capmatinib is combined with Lidocaine.]
[D07XB03, fluprednidene, The metabolism of Lidocaine can be increased when combined with Fluprednidene.]
[P01BE01, artemisinin, The risk or severity of methemoglobinemia can be increased when Artemisinin is combined with Lidocaine.]
[G04BD09, trospium, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[L01EX19, ripretinib, The risk or severity of methemoglobinemia can be increased when Ripretinib is combined with Lidocaine.]
[L01EX22, selpercatinib, The risk or severity of methemoglobinemia can be increased when Selpercatinib is combined with Lidocaine.]
[N05CM02, chlormethiazole, The risk or severity of methemoglobinemia can be increased when Clomethiazole is combined with Lidocaine.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Lidocaine is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Dyclonine.]
[L01XX69, lurbinectedin, The risk or severity of methemoglobinemia can be increased when Lurbinectedin is combined with Lidocaine.]
[C08CA17, levamlodipine, The metabolism of Levamlodipine can be decreased when combined with Lidocaine.]
[P01BB01, proguanil, The risk or severity of methemoglobinemia can be increased when Proguanil is combined with Lidocaine.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Lidocaine is combined with Remimazolam.]
[L01FX12, tafasitamab, The risk or severity of methemoglobinemia can be increased when Tafasitamab is combined with Lidocaine.]
[L01XL06, brexucabtagene autoleucel, The risk or severity of methemoglobinemia can be increased when Brexucabtagene autoleucel is combined with Lidocaine.]
[L01DB04, aclarubicin, The risk or severity of methemoglobinemia can be increased when Aclarubicin is combined with Lidocaine.]
[L04AC19, satralizumab, The serum concentration of Lidocaine can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Lidocaine is combined with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Lidocaine can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Lidocaine.]
[G03CA06, chlorotrianisene, The risk or severity of methemoglobinemia can be increased when Chlorotrianisene is combined with Lidocaine.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Lidocaine can be decreased when combined with Chlorpromazine.]
[N05AF03, chlorprothixene, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[S01AA02, chlortetracycline, The risk or severity of methemoglobinemia can be increased when Chlortetracycline is combined with Lidocaine.]
[M03BB03, chlorzoxazone, The metabolism of Chlorzoxazone can be decreased when combined with Lidocaine.]
[A11CC05, cholecalciferol, The metabolism of Lidocaine can be decreased when combined with Cholecalciferol.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Etifoxine.]
[N06BX18, vinpocetine, Lidocaine may increase the arrhythmogenic activities of Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Lidocaine is combined with Ethyl loflazepate.]
[B06AC06, berotralstat, The metabolism of Lidocaine can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Lidocaine can be decreased when combined with Lonafarnib.]
[M09AA01, hydroquinine, Lidocaine may increase the arrhythmogenic activities of Hydroquinine.]
[L01BB05, fludarabine, The risk or severity of methemoglobinemia can be increased when Fludarabine is combined with Lidocaine.]
[L02BX04, relugolix, The metabolism of Relugolix can be decreased when combined with Lidocaine.]
[L01FD06, margetuximab, The risk or severity of methemoglobinemia can be increased when Margetuximab is combined with Lidocaine.]
[P03AX07, abametapir, The serum concentration of Lidocaine can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The risk or severity of methemoglobinemia can be increased when Tepotinib is combined with Lidocaine.]
[L01EX25, umbralisib, The risk or severity of methemoglobinemia can be increased when Umbralisib is combined with Lidocaine.]
[V03AF12, trilaciclib, The metabolism of Lidocaine can be increased when combined with Trilaciclib.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Lidocaine is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of methemoglobinemia can be increased when Felbamate is combined with Lidocaine.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be decreased when combined with Lidocaine.]
[G04CB01, finasteride, The metabolism of Finasteride can be decreased when combined with Lidocaine.]
[J01DD08, cefixime, The risk or severity of methemoglobinemia can be increased when Cefixime is combined with Lidocaine.]
[J01DD15, cefdinir, The risk or severity of methemoglobinemia can be increased when Cefdinir is combined with Lidocaine.]
[J01MB07, flumequine, The risk or severity of methemoglobinemia can be increased when Flumequine is combined with Lidocaine.]
[R03CC15, formoterol, The metabolism of Formoterol can be decreased when combined with Lidocaine.]
[L04AA50, ponesimod, The metabolism of Ponesimod can be decreased when combined with Lidocaine.]
[S01LA08, bevacizumab, The risk or severity of methemoglobinemia can be increased when Bevacizumab is combined with Lidocaine.]
[L01EK03, tivozanib, The risk or severity of methemoglobinemia can be increased when Tivozanib is combined with Lidocaine.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Lidocaine is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Lidocaine can be increased when it is combined with Peginterferon alfa-2b.]
[L01XL07, idecabtagene vicleucel, The risk or severity of methemoglobinemia can be increased when Idecabtagene vicleucel is combined with Lidocaine.]
[L01FF07, dostarlimab, The risk or severity of methemoglobinemia can be increased when Dostarlimab is combined with Lidocaine.]
[L01FX22, loncastuximab tesirine, The risk or severity of methemoglobinemia can be increased when Loncastuximab tesirine is combined with Lidocaine.]
[A02BA01, cimetidine, The serum concentration of Lidocaine can be increased when it is combined with Cimetidine.]
[R02AB03, fusafungin, The risk or severity of methemoglobinemia can be increased when Fusafungine is combined with Lidocaine.]
[N02BF01, gabapentin, The risk or severity of methemoglobinemia can be increased when Gabapentin is combined with Lidocaine.]
[N07CA02, cinnarizine, Lidocaine may increase the arrhythmogenic activities of Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of methemoglobinemia can be increased when Cinoxacin is combined with Lidocaine.]
[L01XX73, sotorasib, The serum concentration of Lidocaine can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Lidocaine.]
[S03AA07, ciprofloxacin, The risk or severity of methemoglobinemia can be increased when Ciprofloxacin is combined with Lidocaine.]
[L01XA01, cisplatin, The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Lidocaine.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Lidocaine is combined with Citalopram.]
[H01AC07, somapacitan, The metabolism of Lidocaine can be increased when combined with Somapacitan.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Lidocaine.]
[L01XX74, belzutifan, The risk or severity of methemoglobinemia can be increased when Belzutifan is combined with Lidocaine.]
[H01AC09, lonapegsomatropin, The metabolism of Lidocaine can be increased when combined with Lonapegsomatropin.]
[L01EB10, mobocertinib, The metabolism of Mobocertinib can be decreased when combined with Lidocaine.]
[L01FX23, tisotumab vedotin, The risk or severity of methemoglobinemia can be increased when Tisotumab vedotin is combined with Lidocaine.]
[V09IA09, technetium Tc 99m tilmanocept, Lidocaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Clemastine.]
[J01FF01, clindamycin, The risk or severity of methemoglobinemia can be increased when Clindamycin is combined with Lidocaine.]
[N06AX25, St. John's wort extract, The metabolism of Lidocaine can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The risk or severity of methemoglobinemia can be increased when Asciminib is combined with Lidocaine.]
[L02BG06, exemestane, The risk or severity of methemoglobinemia can be increased when Exemestane is combined with Lidocaine.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Lidocaine.]
[L01XX75, tebentafusp, The risk or severity of methemoglobinemia can be increased when Tebentafusp is combined with Lidocaine.]
[J04BA01, clofazimine, The risk or severity of methemoglobinemia can be increased when Clofazimine is combined with Lidocaine.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The metabolism of Lidocaine can be decreased when combined with Pacritinib.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Lidocaine.]
[N03AE01, clonazepam, The risk or severity of methemoglobinemia can be increased when Clonazepam is combined with Lidocaine.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Lidocaine.]
[C01EB24, mavacamten, The serum concentration of Lidocaine can be decreased when it is combined with Mavacamten.]
[A02BC08, vonoprazan, The metabolism of Vonoprazan can be decreased when combined with Lidocaine.]
[L01FX20, tremelimumab, The risk or severity of methemoglobinemia can be increased when Tremelimumab is combined with Lidocaine.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Lidocaine is combined with Clotiazepam.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be decreased when combined with Lidocaine.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Lidocaine is combined with Granisetron.]
[J01CF02, cloxacillin, The risk or severity of methemoglobinemia can be increased when Cloxacillin is combined with Lidocaine.]
[L01XX77, adagrasib, The risk or severity of methemoglobinemia can be increased when Adagrasib is combined with Lidocaine.]
[N05AH02, clozapine, The metabolism of Lidocaine can be decreased when combined with Clozapine.]
[L01EN04, futibatinib, The risk or severity of methemoglobinemia can be increased when Futibatinib is combined with Lidocaine.]
[L01FE02, panitumumab, The risk or severity of methemoglobinemia can be increased when Panitumumab is combined with Lidocaine.]
[J01GB12, arbekacin, The risk or severity of methemoglobinemia can be increased when Arbekacin is combined with Lidocaine.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Lidocaine is combined with Halazepam.]
[L01EX11, quizartinib, The risk or severity of methemoglobinemia can be increased when Quizartinib is combined with Lidocaine.]
[H01AC08, somatrogon, The metabolism of Lidocaine can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of seizure can be increased when Lidocaine is combined with Cocaine.]
[C02KB01, metyrosine, Lidocaine may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Lidocaine can be increased when combined with Bimekizumab.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Codeine.]
[J01CA18, hetacillin, The risk or severity of methemoglobinemia can be increased when Hetacillin is combined with Lidocaine.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Lidocaine is combined with Hexafluronium.]
[A03AB10, hexocyclium, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[J01XX04, spectinomycin, The risk or severity of methemoglobinemia can be increased when Spectinomycin is combined with Lidocaine.]
[A03BB06, homatropine methylbromide, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[J01XB01, colistin, The risk or severity of methemoglobinemia can be increased when Colistin is combined with Lidocaine.]
[L01XX40, omacetaxine mepesuccinate, The risk or severity of methemoglobinemia can be increased when Omacetaxine mepesuccinate is combined with Lidocaine.]
[J01DE02, cefpirome, The risk or severity of methemoglobinemia can be increased when Cefpirome is combined with Lidocaine.]
[L04AA13, leflunomide, The serum concentration of Lidocaine can be decreased when it is combined with Leflunomide.]
[C01BA13, hydroquinidine, Lidocaine may increase the arrhythmogenic activities of Hydroquinidine.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Lidocaine is combined with Desflurane.]
[A04AA03, tropisetron, Lidocaine may increase the arrhythmogenic activities of Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of methemoglobinemia can be increased when Ifenprodil is combined with Lidocaine.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Lidocaine.]
[L01BB07, nelarabine, The risk or severity of methemoglobinemia can be increased when Nelarabine is combined with Lidocaine.]
[J01FA15, telithromycin, The metabolism of Lidocaine can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Lidocaine.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Desloratadine.]
[A03AX10, isometheptene, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Isometheptene.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Lidocaine is combined with Almotriptan.]
[J02AC02, itraconazole, The metabolism of Lidocaine can be decreased when combined with Itraconazole.]
[S01AD03, acyclovir, The metabolism of Acyclovir can be decreased when combined with Lidocaine.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Lidocaine is combined with Ketazolam.]
[L02BA03, fulvestrant, The risk or severity of methemoglobinemia can be increased when Fulvestrant is combined with Lidocaine.]
[L01EA01, imatinib, The serum concentration of Lidocaine can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Lidocaine can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, Lidocaine may increase the arrhythmogenic activities of Lacidipine.]
[V03AF07, rasburicase, The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Lidocaine.]
[N03AX09, lamotrigine, Lidocaine may increase the arrhythmogenic activities of Lamotrigine.]
[S01BA03, cortisone, The metabolism of Lidocaine can be increased when combined with Cortisone.]
[N07BC04, lofexidine, The therapeutic efficacy of Lidocaine can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of methemoglobinemia can be increased when Lomefloxacin is combined with Lidocaine.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Lidocaine is combined with Lormetazepam.]
[J01DC08, loracarbef, The risk or severity of methemoglobinemia can be increased when Loracarbef is combined with Lidocaine.]
[C08CA11, manidipine, Lidocaine may increase the arrhythmogenic activities of Manidipine.]
[A03AA04, mebeverine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[D10AF04, meclocycline, The risk or severity of methemoglobinemia can be increased when Meclocycline is combined with Lidocaine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Medifoxamine.]
[C07AA14, mepindolol, The serum concentration of Lidocaine can be increased when it is combined with Mepindolol.]
[H02AB15, meprednisone, The metabolism of Lidocaine can be increased when combined with Meprednisone.]
[R06AD07, mequitazine, The metabolism of Mequitazine can be decreased when combined with Lidocaine.]
[J01DH02, meropenem, The risk or severity of methemoglobinemia can be increased when Meropenem is combined with Lidocaine.]
[C01EB10, adenosine, Lidocaine may increase the arrhythmogenic activities of Adenosine.]
[J01CA14, methampicillin, The risk or severity of methemoglobinemia can be increased when Metampicillin is combined with Lidocaine.]
[N04AA03, methixene, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[C04AX01, cyclandelate, Lidocaine may increase the arrhythmogenic activities of Cyclandelate.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Lidocaine is combined with Cyclobarbital.]
[C03DA04, eplerenone, The metabolism of Eplerenone can be decreased when combined with Lidocaine.]
[N05AD03, metylperon, Lidocaine may increase the arrhythmogenic activities of Melperone.]
[S01AA22, micronomicin, The risk or severity of methemoglobinemia can be increased when Micronomicin is combined with Lidocaine.]
[J01FA03, midecamycin, The risk or severity of methemoglobinemia can be increased when Midecamycin is combined with Lidocaine.]
[L01AA01, cyclophosphamide, The risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Lidocaine.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Minaprine.]
[J04AB01, cycloserine, The risk or severity of methemoglobinemia can be increased when Cycloserine is combined with Lidocaine.]
[S01XA18, cyclosporine, The metabolism of Lidocaine can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Lidocaine is combined with Moclobemide.]
[N06BA07, modafinil, The metabolism of Lidocaine can be increased when combined with Modafinil.]
[R06AX02, cyproheptadine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be decreased when combined with Lidocaine.]
[C03XA02, conivaptan, The metabolism of Lidocaine can be decreased when combined with Conivaptan.]
[L01BC01, cytarabine, The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Lidocaine.]
[J05AF10, entecavir, The metabolism of Entecavir can be decreased when combined with Lidocaine.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Lidocaine.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be decreased when combined with Lidocaine.]
[L01AX04, dacarbazine, The risk or severity of methemoglobinemia can be increased when Dacarbazine is combined with Lidocaine.]
[L01DA01, dactinomycin, The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Lidocaine.]
[G03XA01, danazol, The metabolism of Lidocaine can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Lidocaine is combined with Dantrolene.]
[J04BA02, dapsone, The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Lidocaine.]
[L01DB02, daunorubicin, The risk or severity of methemoglobinemia can be increased when Daunorubicin is combined with Lidocaine.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Lidocaine is combined with Deanol.]
[C02CC04, debrisoquin, The metabolism of Debrisoquine can be decreased when combined with Lidocaine.]
[L01DB09, valrubicin, The risk or severity of methemoglobinemia can be increased when Valrubicin is combined with Lidocaine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.]
[M01AX01, nabumetone, The metabolism of Nabumetone can be decreased when combined with Lidocaine.]
[J01AA01, demeclocycline, The risk or severity of methemoglobinemia can be increased when Demeclocycline is combined with Lidocaine.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Lidocaine is combined with Nordazepam.]
[C07AB12, nebivolol, The serum concentration of Lidocaine can be increased when it is combined with Nebivolol.]
[N06AX06, nefazodone, The metabolism of Lidocaine can be decreased when combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Niaprazine.]
[C01DX16, nicorandil, Lidocaine may increase the arrhythmogenic activities of Nicorandil.]
[L02BB02, nilutamide, The risk or severity of methemoglobinemia can be increased when Nilutamide is combined with Lidocaine.]
[L01FE01, cetuximab, The risk or severity of methemoglobinemia can be increased when Cetuximab is combined with Lidocaine.]
[N03AG06, tiagabine, The risk or severity of methemoglobinemia can be increased when Tiagabine is combined with Lidocaine.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Lidocaine.]
[M03AC11, cisatracurium, Lidocaine may increase the neuromuscular blocking activities of Cisatracurium.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Lidocaine is combined with Normethadone.]
[N06AB10, escitalopram, The serum concentration of Lidocaine can be increased when it is combined with Escitalopram.]
[G04BD08, solifenacin, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[R02AA02, dequalinium, The risk or severity of methemoglobinemia can be increased when Dequalinium is combined with Lidocaine.]
[N06AA01, desipramine, The metabolism of Lidocaine can be decreased when combined with Desipramine.]
[C01AA07, deslanoside, Lidocaine may increase the arrhythmogenic activities of Deslanoside.]
[J01DH03, ertapenem, The risk or severity of methemoglobinemia can be increased when Ertapenem is combined with Lidocaine.]
[L01XA03, oxaliplatin, The risk or severity of methemoglobinemia can be increased when Oxaliplatin is combined with Lidocaine.]
[N03AF02, oxcarbazepine, The risk or severity of methemoglobinemia can be increased when Oxcarbazepine is combined with Lidocaine.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Lidocaine is combined with Oxiracetam.]
[N04AA08, dexetimide, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Lidocaine.]
[A03AA01, oxyphencyclimine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Lidocaine can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The risk or severity of methemoglobinemia can be increased when Gefitinib is combined with Lidocaine.]
[N06BA02, dextroamphetamine, The metabolism of Amphetamine can be decreased when combined with Lidocaine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Lidocaine is combined with Dextromethorphan.]
[N03AC01, paramethadione, The risk or severity of methemoglobinemia can be increased when Paramethadione is combined with Lidocaine.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Lidocaine is combined with Dextromoramide.]
[N06AB05, paroxetine, The metabolism of Lidocaine can be decreased when combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be decreased when combined with Lidocaine.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Lidocaine is combined with Diamorphine.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Lidocaine.]
[N05BA01, diazepam, The risk or severity of methemoglobinemia can be increased when Diazepam is combined with Lidocaine.]
[N03AX07, phenacemide, The risk or severity of methemoglobinemia can be increased when Phenacemide is combined with Lidocaine.]
[J01CE05, phenethicillin, The risk or severity of methemoglobinemia can be increased when Pheneticillin is combined with Lidocaine.]
[S01AA29, dibekacin, The risk or severity of methemoglobinemia can be increased when Dibekacin is combined with Lidocaine.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Phenol.]
[N03AD02, phensuximide, The risk or severity of methemoglobinemia can be increased when Phensuximide is combined with Lidocaine.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Lidocaine is combined with Dibenzepin.]
[J01CF01, dicloxacillin, The risk or severity of methemoglobinemia can be increased when Dicloxacillin is combined with Lidocaine.]
[A03AA07, dicyclomine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[A03AX04, pinaverium, Lidocaine may increase the arrhythmogenic activities of Pinaverium.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Lidocaine is combined with Pipamperone.]
[A03AB14, pipenzolate, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01DC04, ixabepilone, The risk or severity of methemoglobinemia can be increased when Ixabepilone is combined with Lidocaine.]
[L01EB02, erlotinib, The risk or severity of methemoglobinemia can be increased when Erlotinib is combined with Lidocaine.]
[L01DB08, pirarubicin, The risk or severity of methemoglobinemia can be increased when Pirarubicin is combined with Lidocaine.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Lidocaine is combined with Diethylpropion.]
[C08CA03, isradipine, Isradipine may increase the arrhythmogenic activities of Lidocaine.]
[D07XC04, diflucortolone, The metabolism of Lidocaine can be increased when combined with Difluocortolone.]
[A03AB11, poldine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[C01AA04, digitoxin, Lidocaine may increase the arrhythmogenic activities of Digitoxin.]
[C01AA05, digoxin, Lidocaine may increase the arrhythmogenic activities of Digoxin.]
[C02DB01, dihydralazine, The metabolism of Dihydralazine can be decreased when combined with Lidocaine.]
[L01XX24, pegaspargase, The risk or severity of methemoglobinemia can be increased when Pegaspargase is combined with Lidocaine.]
[C04AE04, dihydroergocristine, The risk or severity of hypertension can be increased when Dihydroergocristine is combined with Lidocaine.]
[N02CA01, dihydroergotamine, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Lidocaine.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Lidocaine is combined with Hydromorphone.]
[L04AX04, lenalidomide, The risk or severity of methemoglobinemia can be increased when Lenalidomide is combined with Lidocaine.]
[J05AE08, atazanavir, The metabolism of Lidocaine can be decreased when combined with Atazanavir.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Pramocaine.]
[C08DB01, diltiazem, Lidocaine may increase the arrhythmogenic activities of Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Lidocaine is combined with Dimenhydrinate.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Lidocaine is combined with Pridinol.]
[R06AB03, dimethindene, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[M02AX03, dimethyl sulfoxide, The metabolism of Lidocaine can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The risk or severity of methemoglobinemia can be increased when Progabide is combined with Lidocaine.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Lidocaine.]
[J01CE03, propicillin, The risk or severity of methemoglobinemia can be increased when Propicillin is combined with Lidocaine.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Proparacaine.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Lidocaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Lidocaine is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Lidocaine is combined with Quazepam.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Lidocaine is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Quinupramine.]
[A03FA02, cisapride, The metabolism of Lidocaine can be decreased when combined with Cisapride.]
[S01XA23, sirolimus, The risk or severity of methemoglobinemia can be increased when Sirolimus is combined with Lidocaine.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Lidocaine is combined with Remoxipride.]
[C01BA03, disopyramide, Disopyramide may increase the arrhythmogenic activities of Lidocaine.]
[P03AA04, disulfiram, The metabolism of Disulfiram can be decreased when combined with Lidocaine.]
[J04AB05, rifapentine, The risk or severity of methemoglobinemia can be increased when Rifapentine is combined with Lidocaine.]
[D06AX11, rifaximin, The risk or severity of methemoglobinemia can be increased when Rifaximin is combined with Lidocaine.]
[N07XX02, riluzole, The risk or severity of methemoglobinemia can be increased when Riluzole is combined with Lidocaine.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Lidocaine is combined with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Ropivacaine.]
[J01MB01, rosoxacin, The risk or severity of methemoglobinemia can be increased when Rosoxacin is combined with Lidocaine.]
[L01EX01, sunitinib, The risk or severity of methemoglobinemia can be increased when Sunitinib is combined with Lidocaine.]
[A04AD12, aprepitant, The metabolism of Lidocaine can be decreased when combined with Aprepitant.]
[L01XG01, bortezomib, The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Lidocaine.]
[G04BE08, tadalafil, The metabolism of Tadalafil can be decreased when combined with Lidocaine.]
[C02KX02, ambrisentan, The metabolism of Ambrisentan can be decreased when combined with Lidocaine.]
[C01EB18, ranolazine, The serum concentration of Lidocaine can be increased when it is combined with Ranolazine.]
[R03AC12, salmeterol, The metabolism of Salmeterol can be decreased when combined with Lidocaine.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Lidocaine.]
[N06AA16, dothiepin, The metabolism of Lidocaine can be decreased when combined with Dosulepin.]
[N06AA12, doxepin, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L01DB01, doxorubicin, The risk or severity of methemoglobinemia can be increased when Doxorubicin is combined with Lidocaine.]
[J01AA02, doxycycline, The risk or severity of methemoglobinemia can be increased when Doxycycline is combined with Lidocaine.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Lidocaine is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Lidocaine is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Lidocaine.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Lidocaine is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of hypertension can be increased when Sumatriptan is combined with Lidocaine.]
[C07AB13, talinolol, The serum concentration of Lidocaine can be increased when it is combined with Talinolol.]
[J01MA05, temafloxacin, The risk or severity of methemoglobinemia can be increased when Temafloxacin is combined with Lidocaine.]
[J01CA17, temocillin, The risk or severity of methemoglobinemia can be increased when Temocillin is combined with Lidocaine.]
[L01AX03, temozolomide, The risk or severity of methemoglobinemia can be increased when Temozolomide is combined with Lidocaine.]
[D01BA02, terbinafine, The metabolism of Lidocaine can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, Lidocaine may increase the arrhythmogenic activities of Terodiline.]
[C07AA16, tertatolol, The serum concentration of Lidocaine can be increased when it is combined with Tertatolol.]
[S01GA02, tetrahydrozoline, The risk or severity of hypertension can be increased when Tetryzoline is combined with Lidocaine.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Lidocaine is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Lidocaine is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Lidocaine is combined with Thiopropazate.]
[G04BD01, emepronium, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Tianeptine.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Lidocaine is combined with Tofisopam.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Lidocaine is combined with Toloxatone.]
[N06BA09, atomoxetine, The metabolism of Atomoxetine can be decreased when combined with Lidocaine.]
[N03AX11, topiramate, The risk or severity of methemoglobinemia can be increased when Topiramate is combined with Lidocaine.]
[L02BA02, toremifene, The risk or severity of methemoglobinemia can be increased when Toremifene is combined with Lidocaine.]
[J01AA12, tigecycline, The risk or severity of methemoglobinemia can be increased when Tigecycline is combined with Lidocaine.]
[L01AB02, treosulfan, The risk or severity of methemoglobinemia can be increased when Treosulfan is combined with Lidocaine.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Lidocaine is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Lidocaine is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Lidocaine is combined with Triclofos.]
[A03AB08, tridihexethyl, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[H02CA01, trilostane, The risk or severity of methemoglobinemia can be increased when Trilostane is combined with Lidocaine.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Lidocaine is combined with Trimethobenzamide.]
[L02AE04, triptorelin, The risk or severity of methemoglobinemia can be increased when Triptorelin is combined with Lidocaine.]
[L01AA07, trofosfamide, The risk or severity of methemoglobinemia can be increased when Trofosfamide is combined with Lidocaine.]
[N04AA12, tropatepine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Lidocaine.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Lidocaine is combined with Urapidil.]
[J01MA04, enoxacin, The risk or severity of methemoglobinemia can be increased when Enoxacin is combined with Lidocaine.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Lidocaine is combined with Veralipride.]
[L01CA04, vinorelbine, The risk or severity of methemoglobinemia can be increased when Vinorelbine is combined with Lidocaine.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Epinastine.]
[N06AX16, venlafaxine, The metabolism of Lidocaine can be decreased when combined with Venlafaxine.]
[S01GA03, xylometazoline, The risk or severity of hypertension can be increased when Xylometazoline is combined with Lidocaine.]
[C08CA12, mepirodipine, Lidocaine may increase the arrhythmogenic activities of Barnidipine.]
[L01DB03, epirubicin, The risk or severity of methemoglobinemia can be increased when Epirubicin is combined with Lidocaine.]
[N05CF02, zolpidem, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[N03AX15, zonisamide, Lidocaine may increase the arrhythmogenic activities of Zonisamide.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Lidocaine is combined with Zopiclone.]
[N05AX11, zotepine, The metabolism of Zotepine can be decreased when combined with Lidocaine.]
[L01XA02, carboplatin, The risk or severity of methemoglobinemia can be increased when Carboplatin is combined with Lidocaine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Guanfacine.]
[C01BG01, moricizine, Lidocaine may increase the arrhythmogenic activities of Moricizine.]
[G02AB03, ergonovine, The risk or severity of hypertension can be increased when Ergometrine is combined with Lidocaine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of hypertension can be increased when Ergoloid mesylate is combined with Lidocaine.]
[N02CA02, ergotamine, The risk or severity of hypertension can be increased when Ergotamine is combined with Lidocaine.]
[N03AG01, valproic acid, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Lidocaine.]
[S01AA17, erythromycin, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Lidocaine.]
[N05CD04, estazolam, The risk or severity of methemoglobinemia can be increased when Estazolam is combined with Lidocaine.]
[H05BX01, cinacalcet, The metabolism of Lidocaine can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Estradiol can be decreased when combined with Lidocaine.]
[L01XX11, estramustine, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Lidocaine.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Conjugated estrogens can be decreased when combined with Lidocaine.]
[J04AK02, ethambutol, The risk or severity of methemoglobinemia can be increased when Ethambutol is combined with Lidocaine.]
[R03BA05, fluticasone, The metabolism of Lidocaine can be decreased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Lidocaine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Lidocaine.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be decreased when combined with Lidocaine.]
[J04AD03, ethionamide, The risk or severity of methemoglobinemia can be increased when Ethionamide is combined with Lidocaine.]
[C01BD05, ibutilide, Lidocaine may increase the arrhythmogenic activities of Ibutilide.]
[L01AG01, ethoglucid, The risk or severity of methemoglobinemia can be increased when Etoglucid is combined with Lidocaine.]
[N04AA05, profenamine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, Lidocaine may increase the arrhythmogenic activities of Ethosuximide.]
[N03AB01, ethotoin, The risk or severity of methemoglobinemia can be increased when Ethotoin is combined with Lidocaine.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Meloxicam.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Ethylmorphine.]
[C01CA01, etilefrine, The risk or severity of hypertension can be increased when Etilefrine is combined with Lidocaine.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Etidocaine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Lidocaine is combined with Etomidate.]
[L01CB01, etoposide, The risk or severity of methemoglobinemia can be increased when Etoposide is combined with Lidocaine.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Lidocaine is combined with Sertindole.]
[C01BA05, ajmaline, Lidocaine may increase the arrhythmogenic activities of Ajmaline.]
[L04AD02, tacrolimus, The metabolism of Tacrolimus can be decreased when combined with Lidocaine.]
[J01MA08, fleroxacin, The risk or severity of methemoglobinemia can be increased when Fleroxacin is combined with Lidocaine.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Lidocaine.]
[R06AX12, terfenadine, The metabolism of Lidocaine can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, The risk or severity of methemoglobinemia can be increased when Trimetrexate is combined with Lidocaine.]
[N06AX12, bupropion, The risk or severity of seizure can be increased when Bupropion is combined with Lidocaine.]
[N06AB08, fluvoxamine, The metabolism of Lidocaine can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, Lidocaine may increase the arrhythmogenic activities of Tocainide.]
[C01BC08, encainide, Lidocaine may increase the arrhythmogenic activities of Encainide.]
[R01AX06, mupirocin, The risk or severity of methemoglobinemia can be increased when Mupirocin is combined with Lidocaine.]
[L02AE02, leuprolide, The risk or severity of methemoglobinemia can be increased when Leuprolide is combined with Lidocaine.]
[A02BA03, famotidine, The metabolism of Lidocaine can be decreased when combined with Famotidine.]
[P02CA03, albendazole, The metabolism of Lidocaine can be increased when combined with Albendazole.]
[C08CA02, felodipine, Lidocaine may increase the arrhythmogenic activities of Felodipine.]
[C08EA01, fendiline, Lidocaine may increase the arrhythmogenic activities of Fendiline.]
[N03AX26, fenfluramine, The risk or severity of methemoglobinemia can be increased when Fenfluramine is combined with Lidocaine.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Lidocaine is combined with Fentanyl.]
[L01BB06, clofarabine, The risk or severity of methemoglobinemia can be increased when Clofarabine is combined with Lidocaine.]
[L04AA40, cladribine, The risk or severity of methemoglobinemia can be increased when Cladribine is combined with Lidocaine.]
[N07AX03, cevimeline, The metabolism of Cevimeline can be decreased when combined with Lidocaine.]
[G04BD02, flavoxate, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, Lidocaine may increase the arrhythmogenic activities of Flecainide.]
[J01CF05, floxacillin, The risk or severity of methemoglobinemia can be increased when Flucloxacillin is combined with Lidocaine.]
[J02AC01, fluconazole, The metabolism of Lidocaine can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, Lidocaine may increase the arrhythmogenic activities of Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Lidocaine is combined with Flunitrazepam.]
[D07AC08, fluocinonide, The metabolism of Lidocaine can be increased when combined with Fluocinonide.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Lidocaine is combined with Melitracen.]
[H02AB03, fluocortolone, The metabolism of Lidocaine can be increased when combined with Fluocortolone.]
[V03AZ01, ethanol, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC09, floxuridine, The risk or severity of methemoglobinemia can be increased when Floxuridine is combined with Lidocaine.]
[L01BC02, fluorouracil, The risk or severity of methemoglobinemia can be increased when Fluorouracil is combined with Lidocaine.]
[N06AB03, fluoxetine, The serum concentration of Lidocaine can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Fluphenazine.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Lidocaine is combined with Flurazepam.]
[N05AG01, fluspirilene, Lidocaine may increase the arrhythmogenic activities of Fluspirilene.]
[L02BB01, flutamide, The risk or severity of methemoglobinemia can be increased when Flutamide is combined with Lidocaine.]
[S02AA17, fosfomycin, The risk or severity of methemoglobinemia can be increased when Fosfomycin is combined with Lidocaine.]
[S01AA07, framycetin, The risk or severity of methemoglobinemia can be increased when Framycetin is combined with Lidocaine.]
[L01BC03, tegafur, The risk or severity of methemoglobinemia can be increased when Tegafur is combined with Lidocaine.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Lidocaine is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Lidocaine is combined with Furazolidone.]
[J05AE10, darunavir, The metabolism of Lidocaine can be decreased when combined with Darunavir.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Lidocaine is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Lidocaine is combined with Amisulpride.]
[N06DA04, galantamine, The metabolism of Galantamine can be decreased when combined with Lidocaine.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Gallamine.]
[C08DA02, gallopamil, Lidocaine may increase the arrhythmogenic activities of Gallopamil.]
[N03AA04, barbexaclone, The risk or severity of methemoglobinemia can be increased when Barbexaclone is combined with Lidocaine.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Lidocaine is combined with Bifemelane.]
[C10AB04, gemfibrozil, The metabolism of Lidocaine can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of methemoglobinemia can be increased when Telavancin is combined with Lidocaine.]
[L02BX02, degarelix, The risk or severity of methemoglobinemia can be increased when Degarelix is combined with Lidocaine.]
[L01EA02, dasatinib, The risk or severity of methemoglobinemia can be increased when Dasatinib is combined with Lidocaine.]
[N04BC06, cabergoline, The risk or severity of hypertension can be increased when Cabergoline is combined with Lidocaine.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Lidocaine.]
[N03AD03, methsuximide, Lidocaine may increase the arrhythmogenic activities of Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Lidocaine is combined with Alfentanil.]
[L01EH01, lapatinib, The risk or severity of methemoglobinemia can be increased when Lapatinib is combined with Lidocaine.]
[A10BB01, glyburide, The metabolism of Glyburide can be decreased when combined with Lidocaine.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Dexmedetomidine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Lidocaine is combined with Glutethimide.]
[C05AE01, nitroglycerin, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Nitroglycerin.]
[C01BD04, dofetilide, Dofetilide may increase the arrhythmogenic activities of Lidocaine.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Lidocaine.]
[L01EX02, sorafenib, The risk or severity of methemoglobinemia can be increased when Sorafenib is combined with Lidocaine.]
[C07AB09, esmolol, The serum concentration of Lidocaine can be increased when it is combined with Esmolol.]
[R02AB30, gramicidin, The risk or severity of methemoglobinemia can be increased when Gramicidin D is combined with Lidocaine.]
[L02AE03, goserelin, The risk or severity of methemoglobinemia can be increased when Goserelin is combined with Lidocaine.]
[P01BX01, halofantrine, The risk or severity of methemoglobinemia can be increased when Halofantrine is combined with Lidocaine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Lidocaine.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Lidocaine is combined with Halothane.]
[N05AH04, quetiapine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Lidocaine is combined with Iprazochrome.]
[L01CE02, irinotecan, The risk or severity of methemoglobinemia can be increased when Irinotecan is combined with Lidocaine.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Lidocaine is combined with Allobarbital.]
[C09CA01, losartan, Lidocaine may increase the arrhythmogenic activities of Losartan.]
[L01XX03, altretamine, The risk or severity of methemoglobinemia can be increased when Altretamine is combined with Lidocaine.]
[N05CA16, hexobarbital, The risk or severity of methemoglobinemia can be increased when Hexobarbital is combined with Lidocaine.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Lidocaine.]
[C08CA10, nilvadipine, Lidocaine may increase the arrhythmogenic activities of Nilvadipine.]
[M02AA26, nimesulide, Lidocaine may increase the arrhythmogenic activities of Nimesulide.]
[R05DA03, hydrocodone, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[D07AB02, hydrocortisone butyrate, The metabolism of Hydrocortisone butyrate can be decreased when combined with Lidocaine.]
[G04BD06, propiverine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of methemoglobinemia can be increased when Hydroxychloroquine is combined with Lidocaine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Lidocaine is combined with Prothipendyl.]
[L01XX05, hydroxyurea, The risk or severity of methemoglobinemia can be increased when Hydroxyurea is combined with Lidocaine.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.]
[J04AB04, rifabutin, The risk or severity of methemoglobinemia can be increased when Rifabutin is combined with Lidocaine.]
[L01DB06, idarubicin, The risk or severity of methemoglobinemia can be increased when Idarubicin is combined with Lidocaine.]
[L01AA06, ifosfamide, The risk or severity of methemoglobinemia can be increased when Ifosfamide is combined with Lidocaine.]
[H01AC02, somatrem, The metabolism of Lidocaine can be increased when combined with Somatrem.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Lidocaine is combined with Sufentanil.]
[N06AA02, imipramine, The metabolism of Lidocaine can be decreased when combined with Imipramine.]
[L01CD01, paclitaxel, The risk or severity of methemoglobinemia can be increased when Paclitaxel is combined with Lidocaine.]
[L01CD03, paclitaxel poliglumex, The risk or severity of methemoglobinemia can be increased when Paclitaxel poliglumex is combined with Lidocaine.]
[J01XA02, teicoplanin, The risk or severity of methemoglobinemia can be increased when Teicoplanin is combined with Lidocaine.]
[H01BA04, terlipressin, The risk or severity of hypertension can be increased when Terlipressin is combined with Lidocaine.]
[M03BX02, tizanidine, The serum concentration of Tizanidine can be increased when it is combined with Lidocaine.]
[L01CE01, topotecan, The risk or severity of methemoglobinemia can be increased when Topotecan is combined with Lidocaine.]
[L03AB04, interferon alfa-2a, The risk or severity of methemoglobinemia can be increased when Interferon alfa-2a is combined with Lidocaine.]
[L03AB05, interferon alfa-2b, The risk or severity of methemoglobinemia can be increased when Interferon alfa-2b is combined with Lidocaine.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Lidocaine is combined with Milnacipran.]
[A03AA30, piperidolate, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Articaine.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Lidocaine is combined with Alprazolam.]
[N05CH02, ramelteon, The metabolism of Ramelteon can be decreased when combined with Lidocaine.]
[R06AE01, buclizine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C10AA06, cerivastatin, The metabolism of Lidocaine can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of methemoglobinemia can be increased when Anagrelide is combined with Lidocaine.]
[C07AA01, alprenolol, The serum concentration of Lidocaine can be increased when it is combined with Alprenolol.]
[L03AB09, interferon alfacon-1, The metabolism of Lidocaine can be decreased when combined with Interferon alfacon-1.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Lidocaine.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Lidocaine is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Lidocaine is combined with Iproniazid.]
[J05AB13, penciclovir, The metabolism of Penciclovir can be decreased when combined with Lidocaine.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Lidocaine is combined with Isocarboxazid.]
[P01AX06, atovaquone, The risk or severity of methemoglobinemia can be increased when Atovaquone is combined with Lidocaine.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Lidocaine is combined with Isoflurane.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Lidocaine is combined with Entacapone.]
[J04AC01, isoniazid, The risk or severity of methemoglobinemia can be increased when Isoniazid is combined with Lidocaine.]
[C01DA14, isosorbide mononitrate, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Isosorbide mononitrate.]
[C05AE02, isosorbide dinitrate, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Isosorbide dinitrate.]
[J01FA07, josamycin, The risk or severity of methemoglobinemia can be increased when Josamycin is combined with Lidocaine.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Lidocaine.]
[S01AA24, kanamycin, The risk or severity of methemoglobinemia can be increased when Kanamycin is combined with Lidocaine.]
[H01AC01, somatropin, The metabolism of Lidocaine can be increased when combined with Somatotropin.]
[L04AC07, tocilizumab, The metabolism of Lidocaine can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Lidocaine is combined with Ketanserin.]
[H02CA04, levoketoconazole, The metabolism of Lidocaine can be decreased when combined with Levoketoconazole.]
[J02AB02, ketoconazole, The metabolism of Lidocaine can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[V03AC03, deferasirox, The serum concentration of Lidocaine can be increased when it is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Lidocaine can be increased when combined with Abatacept.]
[N04BC09, rotigotine, Lidocaine may increase the sedative activities of Rotigotine.]
[C07AG01, labetalol, The serum concentration of Lidocaine can be increased when it is combined with Labetalol.]
[N03AX18, lacosamide, The risk or severity of methemoglobinemia can be increased when Lacosamide is combined with Lidocaine.]
[J01CA11, amdinocillin, The risk or severity of methemoglobinemia can be increased when Amdinocillin is combined with Lidocaine.]
[J01CA08, amdinocillin pivoxil, The risk or severity of methemoglobinemia can be increased when Pivmecillinam is combined with Lidocaine.]
[L01DC03, mitomycin, The risk or severity of methemoglobinemia can be increased when Mitomycin is combined with Lidocaine.]
[G03AD01, levonorgestrel, The metabolism of Levonorgestrel can be decreased when combined with Lidocaine.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Lidocaine is combined with Levodopa.]
[J01MB04, pipemidic acid, The risk or severity of methemoglobinemia can be increased when Pipemidic acid is combined with Lidocaine.]
[N07XX04, sodium oxybate, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[M01AG01, mefenamic acid, The metabolism of Mefenamic acid can be decreased when combined with Lidocaine.]
[R03BA09, fluticasone furoate, The metabolism of Lidocaine can be decreased when combined with Fluticasone furoate.]
[J01MB02, nalidixic acid, The risk or severity of methemoglobinemia can be increased when Nalidixic acid is combined with Lidocaine.]
[C08EX01, lidoflazine, Lidocaine may increase the arrhythmogenic activities of Lidoflazine.]
[J01FF02, lincomycin, The risk or severity of methemoglobinemia can be increased when Lincomycin is combined with Lidocaine.]
[S01AA21, amikacin, The risk or severity of methemoglobinemia can be increased when Amikacin is combined with Lidocaine.]
[N06BA13, armodafinil, The metabolism of Lidocaine can be increased when combined with Armodafinil.]
[N02CA07, lisuride, The risk or severity of hypertension can be increased when Lisuride is combined with Lidocaine.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Lofepramine.]
[L01AD02, lomustine, The risk or severity of methemoglobinemia can be increased when Lomustine is combined with Lidocaine.]
[A07DA03, loperamide, Lidocaine may increase the arrhythmogenic activities of Loperamide.]
[N05BA06, lorazepam, The risk or severity of methemoglobinemia can be increased when Lorazepam is combined with Lidocaine.]
[C10AA02, lovastatin, The metabolism of Lidocaine can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Loxapine.]
[J01AA04, lymecycline, The risk or severity of methemoglobinemia can be increased when Lymecycline is combined with Lidocaine.]
[H01BA03, lypressin, The risk or severity of hypertension can be increased when Lypressin is combined with Lidocaine.]
[L01EG01, temsirolimus, The risk or severity of methemoglobinemia can be increased when Temsirolimus is combined with Lidocaine.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Lidocaine can be increased when used in combination with Magnesium sulfate.]
[L01BA05, pralatrexate, The risk or severity of methemoglobinemia can be increased when Pralatrexate is combined with Lidocaine.]
[L01EA03, nilotinib, The metabolism of Lidocaine can be decreased when combined with Nilotinib.]
[N06AA21, maprotiline, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Lidocaine is combined with Mazindol.]
[L01AA05, mechlorethamine, The risk or severity of methemoglobinemia can be increased when Mechlorethamine is combined with Lidocaine.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Meclizine.]
[N05BA03, medazepam, The risk or severity of methemoglobinemia can be increased when Medazepam is combined with Lidocaine.]
[C01AA08, medigoxin, Lidocaine may increase the arrhythmogenic activities of Metildigoxin.]
[P01BC02, mefloquine, The risk or severity of methemoglobinemia can be increased when Mefloquine is combined with Lidocaine.]
[J01FG01, pristinamycin, The risk or severity of methemoglobinemia can be increased when Pristinamycin is combined with Lidocaine.]
[N05CH01, melatonin, The metabolism of Melatonin can be decreased when combined with Lidocaine.]
[L01AA03, melphalan, The risk or severity of methemoglobinemia can be increased when Melphalan is combined with Lidocaine.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Meperidine.]
[C01CA11, mephentermine, The risk or severity of hypertension can be increased when Mephentermine is combined with Lidocaine.]
[N03AB04, mephenytoin, The risk or severity of methemoglobinemia can be increased when Mephenytoin is combined with Lidocaine.]
[N03AA01, mephobarbital, The risk or severity of methemoglobinemia can be increased when Methylphenobarbital is combined with Lidocaine.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Lidocaine is combined with Meprobamate.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Lidocaine is combined with Meptazinol.]
[L02BG01, aminoglutethimide, The risk or severity of methemoglobinemia can be increased when Aminoglutethimide is combined with Lidocaine.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Lidocaine is combined with Paliperidone.]
[C01CA09, metaraminol, The risk or severity of hypertension can be increased when Metaraminol is combined with Lidocaine.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Lidocaine is combined with Dolasetron.]
[H01CB03, lanreotide, The risk or severity of methemoglobinemia can be increased when Lanreotide is combined with Lidocaine.]
[J01AA05, methacycline, The risk or severity of methemoglobinemia can be increased when Metacycline is combined with Lidocaine.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Lidocaine.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Metamfetamine.]
[A03AB07, methantheline, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Lidocaine is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Lidocaine is combined with Methaqualone.]
[N03AA30, metharbital, The risk or severity of methemoglobinemia can be increased when Metharbital is combined with Lidocaine.]
[L01XD04, aminolevulinic acid, The risk or severity of methemoglobinemia can be increased when Aminolevulinic acid is combined with Lidocaine.]
[J01XX05, methenamine, The risk or severity of methemoglobinemia can be increased when Methenamine is combined with Lidocaine.]
[G02CB05, metergoline, The risk or severity of hypertension can be increased when Metergoline is combined with Lidocaine.]
[H03BB02, methimazole, The metabolism of Lidocaine can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of methemoglobinemia can be increased when Pemetrexed is combined with Lidocaine.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Lidocaine is combined with Methocarbamol.]
[N05CA15, methohexital, The risk or severity of methemoglobinemia can be increased when Methohexital is combined with Lidocaine.]
[N02BG08, ziconotide, Lidocaine may increase the arrhythmogenic activities of Ziconotide.]
[L04AX03, methotrexate, The risk or severity of methemoglobinemia can be increased when Methotrexate is combined with Lidocaine.]
[N05AA02, methotrimeprazine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of hypertension can be increased when Methoxamine is combined with Lidocaine.]
[D05BA02, methoxsalen, The metabolism of Lidocaine can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Lidocaine is combined with Methoxyflurane.]
[V04CG05, methylene blue, The metabolism of Methylene blue can be decreased when combined with Lidocaine.]
[G02AB01, methylergonovine, The risk or severity of hypertension can be increased when Methylergometrine is combined with Lidocaine.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Lidocaine.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Lidocaine.]
[G03EK01, methyltestosterone, The risk or severity of methemoglobinemia can be increased when Methyltestosterone is combined with Lidocaine.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Lidocaine is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of hypertension can be increased when Methysergide is combined with Lidocaine.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Lidocaine.]
[C07AB02, metoprolol, The serum concentration of Lidocaine can be increased when it is combined with Metoprolol.]
[P01AB01, metronidazole, The risk or severity of methemoglobinemia can be increased when Metronidazole is combined with Lidocaine.]
[C01BB02, mexiletine, Lidocaine may increase the arrhythmogenic activities of Mexiletine.]
[J01CA10, mezlocillin, The risk or severity of methemoglobinemia can be increased when Mezlocillin is combined with Lidocaine.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Lidocaine.]
[S02AA13, miconazole, The metabolism of Lidocaine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Lidocaine.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Lidocaine is combined with Midazolam.]
[C01CA17, midodrine, The risk or severity of hypertension can be increased when Midodrine is combined with Lidocaine.]
[G03XB01, mifepristone, The metabolism of Lidocaine can be decreased when combined with Mifepristone.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.]
[J01FA11, miocamycin, The risk or severity of methemoglobinemia can be increased when Miocamycin is combined with Lidocaine.]
[L01DC02, plicamycin, The risk or severity of methemoglobinemia can be increased when Plicamycin is combined with Lidocaine.]
[L01AX01, mitobronitol, The risk or severity of methemoglobinemia can be increased when Mitobronitol is combined with Lidocaine.]
[L01XX23, mitotane, The risk or severity of methemoglobinemia can be increased when Mitotane is combined with Lidocaine.]
[L01DB07, mitoxantrone, The risk or severity of methemoglobinemia can be increased when Mitoxantrone is combined with Lidocaine.]
[N06BA12, lisdexamfetamine, The metabolism of Lisdexamfetamine can be decreased when combined with Lidocaine.]
[L03AA03, molgramostim, The risk or severity of methemoglobinemia can be increased when Molgramostim is combined with Lidocaine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Lidocaine is combined with Molindone.]
[L03AC01, aldesleukin, The risk or severity of methemoglobinemia can be increased when Aldesleukin is combined with Lidocaine.]
[C01BD01, amiodarone, The risk or severity of generalized seizure and bradycardia can be increased when Amiodarone is combined with Lidocaine.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Lidocaine.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Morphine.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Lidocaine is combined with Palonosetron.]
[J01DD06, moxalactam, The risk or severity of methemoglobinemia can be increased when Latamoxef is combined with Lidocaine.]
[L04AB05, certolizumab pegol, The metabolism of Lidocaine can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Lidocaine.]
[L04AA52, ofatumumab, The risk or severity of methemoglobinemia can be increased when Ofatumumab is combined with Lidocaine.]
[L01EX03, pazopanib, The risk or severity of methemoglobinemia can be increased when Pazopanib is combined with Lidocaine.]
[L04AA06, mycophenolic acid, The risk or severity of methemoglobinemia can be increased when Mycophenolic acid is combined with Lidocaine.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Lidocaine is combined with Vecuronium.]
[N05CA02, amobarbital, The risk or severity of methemoglobinemia can be increased when Amobarbital is combined with Lidocaine.]
[P01BA06, amodiaquine, The risk or severity of methemoglobinemia can be increased when Amodiaquine is combined with Lidocaine.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Lidocaine.]
[N03AB05, fosphenytoin, The risk or severity of methemoglobinemia can be increased when Fosphenytoin is combined with Lidocaine.]
[L03AB08, interferon beta-1b, The metabolism of Lidocaine can be decreased when combined with Interferon beta-1b.]
[C07AA12, nadolol, The serum concentration of Lidocaine can be increased when it is combined with Nadolol.]
[J01CA04, amoxicillin, The risk or severity of methemoglobinemia can be increased when Amoxicillin is combined with Lidocaine.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Lidocaine is combined with Ropinirole.]
[J01CF06, nafcillin, The risk or severity of methemoglobinemia can be increased when Nafcillin is combined with Lidocaine.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Lidocaine is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Nalbuphine.]
[V03AB15, naloxone, The metabolism of Lidocaine can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Lidocaine can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The risk or severity of hypertension can be increased when Naphazoline is combined with Lidocaine.]
[N06BA01, amphetamine, The metabolism of Amphetamine can be decreased when combined with Lidocaine.]
[M02AA12, naproxen, The metabolism of Naproxen can be decreased when combined with Lidocaine.]
[A10BG01, troglitazone, The metabolism of Lidocaine can be decreased when combined with Troglitazone.]
[N06AX21, duloxetine, The metabolism of Lidocaine can be decreased when combined with Duloxetine.]
[S01AA10, natamycin, The risk or severity of methemoglobinemia can be increased when Natamycin is combined with Lidocaine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Lidocaine is combined with Tolcapone.]
[L01CD02, docetaxel, The risk or severity of methemoglobinemia can be increased when Docetaxel is combined with Lidocaine.]
[L02BG04, letrozole, The risk or severity of methemoglobinemia can be increased when Letrozole is combined with Lidocaine.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Lidocaine is combined with Remifentanil.]
[C01CX08, levosimendan, Lidocaine may increase the arrhythmogenic activities of Levosimendan.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Lidocaine is combined with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of methemoglobinemia can be increased when Amphotericin B is combined with Lidocaine.]
[S01AA19, ampicillin, The risk or severity of methemoglobinemia can be increased when Ampicillin is combined with Lidocaine.]
[S01AA23, netilmicin, The risk or severity of methemoglobinemia can be increased when Netilmicin is combined with Lidocaine.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Desvenlafaxine.]
[L01XX01, amsacrine, The risk or severity of methemoglobinemia can be increased when Amsacrine is combined with Lidocaine.]
[C10AD02, niacin, The metabolism of Lidocaine can be decreased when combined with Niacin.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Lidocaine is combined with Nialamide.]
[C08CA04, nicardipine, Lidocaine may increase the arrhythmogenic activities of Nicardipine.]
[C04AE02, nicergoline, The risk or severity of hypertension can be increased when Nicergoline is combined with Lidocaine.]
[P02DA01, niclosamide, The metabolism of Lidocaine can be decreased when combined with Niclosamide.]
[V03AB22, amyl nitrite, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Amyl Nitrite.]
[C08CA06, nimodipine, Lidocaine may increase the arrhythmogenic activities of Nimodipine.]
[C08CA07, nisoldipine, Lidocaine may increase the arrhythmogenic activities of Nisoldipine.]
[N05CD02, nitrazepam, The risk or severity of methemoglobinemia can be increased when Nitrazepam is combined with Lidocaine.]
[C08CA08, nitrendipine, Lidocaine may increase the arrhythmogenic activities of Nitrendipine.]
[R07AX01, nitric oxide, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Nitric Oxide.]
[J01XE01, nitrofurantoin, The risk or severity of methemoglobinemia can be increased when Nitrofurantoin is combined with Lidocaine.]
[N05CF03, zaleplon, The risk or severity of methemoglobinemia can be increased when Zaleplon is combined with Lidocaine.]
[N04BC05, pramipexole, Lidocaine may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Lidocaine is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Nomifensine.]
[C01CA03, norepinephrine, The risk or severity of hypertension can be increased when Norepinephrine is combined with Lidocaine.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be decreased when combined with Lidocaine.]
[S01AE02, norfloxacin, The risk or severity of methemoglobinemia can be increased when Norfloxacin is combined with Lidocaine.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Lidocaine.]
[L03AB07, interferon beta-1a, The metabolism of Lidocaine can be decreased when combined with Interferon beta-1a.]
[G02CA02, nylidrin, Lidocaine may increase the arrhythmogenic activities of Nylidrin.]
[H01CB02, octreotide, The risk or severity of methemoglobinemia can be increased when Octreotide is combined with Lidocaine.]
[S02AA16, ofloxacin, The risk or severity of methemoglobinemia can be increased when Ofloxacin is combined with Lidocaine.]
[J01FA05, oleandomycin, The risk or severity of methemoglobinemia can be increased when Oleandomycin is combined with Lidocaine.]
[L04AC04, rilonacept, The metabolism of Lidocaine can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Lidocaine can be increased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Lidocaine is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Lidocaine is combined with Opium.]
[H01BA05, ornipressin, The risk or severity of hypertension can be increased when Ornipressin is combined with Lidocaine.]
[G04CA02, tamsulosin, The metabolism of Tamsulosin can be decreased when combined with Lidocaine.]
[J01CF04, oxacillin, The risk or severity of methemoglobinemia can be increased when Oxacillin is combined with Lidocaine.]
[P02BA02, oxamniquine, The metabolism of Lidocaine can be decreased when combined with Oxamniquine.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Lidocaine is combined with Oxazepam.]
[J01MB05, oxolinic acid, The risk or severity of methemoglobinemia can be increased when Oxolinic acid is combined with Lidocaine.]
[C07AA02, oxprenolol, The serum concentration of Lidocaine can be increased when it is combined with Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Lidocaine is combined with Oxycodone.]
[S01GA04, oxymetazoline, The risk or severity of hypertension can be increased when Oxymetazoline is combined with Lidocaine.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Lidocaine is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Oxypertine.]
[A03AB03, oxyphenonium, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[S01AA04, oxytetracycline, The risk or severity of methemoglobinemia can be increased when Oxytetracycline is combined with Lidocaine.]
[J04AA01, aminosalicylic acid, The risk or severity of methemoglobinemia can be increased when Aminosalicylic acid is combined with Lidocaine.]
[N05AH05, asenapine, The metabolism of Asenapine can be decreased when combined with Lidocaine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.]
[M03AC01, pancuronium, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[J04AB30, capreomycin, The risk or severity of methemoglobinemia can be increased when Capreomycin is combined with Lidocaine.]
[N05CC05, paraldehyde, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[H02AB05, paramethasone, The metabolism of Lidocaine can be increased when combined with Paramethasone.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Lidocaine is combined with Pargyline.]
[A07AA06, paromomycin, The risk or severity of methemoglobinemia can be increased when Paromomycin is combined with Lidocaine.]
[J01MA03, pefloxacin, The risk or severity of methemoglobinemia can be increased when Pefloxacin is combined with Lidocaine.]
[G04BD11, fesoterodine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The serum concentration of Lidocaine can be increased when it is combined with Penbutolol.]
[N05AG03, penfluridol, Lidocaine may increase the arrhythmogenic activities of Penfluridol.]
[S01AA14, penicillin G, The risk or severity of methemoglobinemia can be increased when Benzylpenicillin is combined with Lidocaine.]
[J01CE09, penicillin G procaine, The risk or severity of methemoglobinemia can be increased when Procaine benzylpenicillin is combined with Lidocaine.]
[J01CE02, penicillin V, The risk or severity of methemoglobinemia can be increased when Phenoxymethylpenicillin is combined with Lidocaine.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Pentazocine.]
[N05CA01, pentobarbital, The risk or severity of methemoglobinemia can be increased when Pentobarbital is combined with Lidocaine.]
[L01XX08, pentostatin, The risk or severity of methemoglobinemia can be increased when Pentostatin is combined with Lidocaine.]
[C04AD03, pentoxifylline, The metabolism of Pentoxifylline can be decreased when combined with Lidocaine.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of hypertension can be increased when Pergolide is combined with Lidocaine.]
[C08EX02, perhexiline, Lidocaine may increase the arrhythmogenic activities of Perhexiline.]
[L01FX01, edrecolomab, The risk or severity of methemoglobinemia can be increased when Edrecolomab is combined with Lidocaine.]
[N05AB03, perphenazine, The metabolism of Perphenazine can be decreased when combined with Lidocaine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Lidocaine.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Phenazocine.]
[G04BX06, phenazopyridine, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Phenazopyridine.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Phenelzine.]
[A10BA01, phenformin, The metabolism of Phenformin can be decreased when combined with Lidocaine.]
[N03AA02, phenobarbital, The risk or severity of methemoglobinemia can be increased when Phenobarbital is combined with Lidocaine.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Phenoperidine.]
[R01BA01, phenylpropanolamine, The risk or severity of hypertension can be increased when Phenylpropanolamine is combined with Lidocaine.]
[N03AB02, phenytoin, The risk or severity of methemoglobinemia can be increased when Phenytoin is combined with Lidocaine.]
[L01XF02, alitretinoin, The risk or severity of methemoglobinemia can be increased when Alitretinoin is combined with Lidocaine.]
[L04AB06, golimumab, The metabolism of Lidocaine can be increased when combined with Golimumab.]
[S01AE08, besifloxacin, The risk or severity of methemoglobinemia can be increased when Besifloxacin is combined with Lidocaine.]
[S01AE05, levofloxacin, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Lidocaine.]
[L02BB03, bicalutamide, The risk or severity of methemoglobinemia can be increased when Bicalutamide is combined with Lidocaine.]
[C08CX01, mibefradil, Lidocaine may increase the arrhythmogenic activities of Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Lidocaine.]
[C07AA03, pindolol, The serum concentration of Lidocaine can be increased when it is combined with Pindolol.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Lidocaine.]
[J01CA12, piperacillin, The risk or severity of methemoglobinemia can be increased when Piperacillin is combined with Lidocaine.]
[J05AE01, saquinavir, The metabolism of Lidocaine can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Piperazine can be decreased when combined with Lidocaine.]
[L01AX02, pipobroman, The risk or severity of methemoglobinemia can be increased when Pipobroman is combined with Lidocaine.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Pipotiazine.]
[A02BX03, pirenzepine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Lidocaine is combined with Piritramide.]
[J01DD16, cefditoren, The risk or severity of methemoglobinemia can be increased when Cefditoren is combined with Lidocaine.]
[J01MA11, grepafloxacin, The risk or severity of methemoglobinemia can be increased when Grepafloxacin is combined with Lidocaine.]
[J01CA02, pivampicillin, The risk or severity of methemoglobinemia can be increased when Pivampicillin is combined with Lidocaine.]
[N02CX01, pizotyline, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Lidocaine can be decreased when combined with Delavirdine.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Lidocaine is combined with Proxibarbal.]
[L02BG03, anastrozole, The risk or severity of methemoglobinemia can be increased when Anastrozole is combined with Lidocaine.]
[A03AE01, alosetron, The metabolism of Alosetron can be decreased when combined with Lidocaine.]
[L04AC08, canakinumab, The metabolism of Lidocaine can be increased when combined with Canakinumab.]
[J05AE03, ritonavir, The serum concentration of Lidocaine can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The metabolism of Saxagliptin can be decreased when combined with Lidocaine.]
[C07AB01, practolol, The serum concentration of Lidocaine can be increased when it is combined with Practolol.]
[C01BA08, prajmaline, Lidocaine may increase the arrhythmogenic activities of Prajmaline.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Lidocaine is combined with Prazepam.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Lidocaine.]
[L01AA08, prednimustine, The risk or severity of methemoglobinemia can be increased when Prednimustine is combined with Lidocaine.]
[S03BA02, prednisolone, The risk or severity of methemoglobinemia can be increased when Prednisolone is combined with Lidocaine.]
[H02AB07, prednisone, The risk or severity of methemoglobinemia can be increased when Prednisone is combined with Lidocaine.]
[C01DX02, prenylamine, Lidocaine may increase the arrhythmogenic activities of Prenylamine.]
[P01BA03, primaquine, The metabolism of Lidocaine can be decreased when combined with Primaquine.]
[N03AA03, primidone, The risk or severity of methemoglobinemia can be increased when Primidone is combined with Lidocaine.]
[C01BA02, procainamide, Lidocaine may increase the arrhythmogenic activities of Procainamide.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of methemoglobinemia can be increased when Procarbazine is combined with Lidocaine.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Prochlorperazine.]
[N04AA04, procyclidine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Lidocaine can be decreased when combined with Progesterone.]
[N05AA03, promazine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Promazine.]
[R06AD02, promethazine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, The serum concentration of Lidocaine can be increased when it is combined with Propafenone.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Lidocaine is combined with Propanidid.]
[A03AB05, propantheline, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Periciazine.]
[N05CM06, propiomazine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[L01XH02, romidepsin, The risk or severity of methemoglobinemia can be increased when Romidepsin is combined with Lidocaine.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Lidocaine is combined with Propofol.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Lidocaine is combined with Dextropropoxyphene.]
[C07AA05, propranolol, The serum concentration of Lidocaine can be increased when it is combined with Propranolol.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Lidocaine is combined with Rizatriptan.]
[J04AD01, prothionamide, The risk or severity of methemoglobinemia can be increased when Protionamide is combined with Lidocaine.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Lidocaine is combined with Protriptyline.]
[R01BA02, pseudoephedrine, The risk or severity of hypertension can be increased when Pseudoephedrine is combined with Lidocaine.]
[N05AX12, aripiprazole, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.]
[N07XX07, dalfampridine, The risk or severity of seizure can be increased when Lidocaine is combined with Dalfampridine.]
[A03AB15, diphemanil, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Lidocaine is combined with Talbutal.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Lidocaine is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Lidocaine is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Lidocaine is combined with Pyrantel.]
[J04AK01, pyrazinamide, The risk or severity of methemoglobinemia can be increased when Pyrazinamide is combined with Lidocaine.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Mepyramine.]
[P01BD01, pyrimethamine, The risk or severity of methemoglobinemia can be increased when Pyrimethamine is combined with Lidocaine.]
[P01AX05, quinacrine, The risk or severity of methemoglobinemia can be increased when Quinacrine is combined with Lidocaine.]
[C01BA01, quinidine, Lidocaine may increase the arrhythmogenic activities of Quinidine.]
[P01BC01, quinine, The metabolism of Lidocaine can be decreased when combined with Quinine.]
[A02BA02, ranitidine, The serum concentration of Lidocaine can be increased when it is combined with Ranitidine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Lidocaine.]
[J04AB02, rifampin, The risk or severity of methemoglobinemia can be increased when Rifampicin is combined with Lidocaine.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Lidocaine is combined with Oxitriptan.]
[J01AA09, rolitetracycline, The risk or severity of methemoglobinemia can be increased when Rolitetracycline is combined with Lidocaine.]
[J01FA06, roxithromycin, The risk or severity of methemoglobinemia can be increased when Roxithromycin is combined with Lidocaine.]
[A07EC01, sulfasalazine, The risk or severity of methemoglobinemia can be increased when Sulfasalazine is combined with Lidocaine.]
[S01FA02, scopolamine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The risk or severity of methemoglobinemia can be increased when Secobarbital is combined with Lidocaine.]
[N04BD01, selegiline, The metabolism of Selegiline can be decreased when combined with Lidocaine.]
[L01FA03, obinutuzumab, The risk or severity of methemoglobinemia can be increased when Obinutuzumab is combined with Lidocaine.]
[D06BA01, silver sulfadiazine, The risk or severity of methemoglobinemia can be increased when Silver sulfadiazine is combined with Lidocaine.]
[J01GB08, sisomicin, The risk or severity of methemoglobinemia can be increased when Sisomicin is combined with Lidocaine.]
[C07AA07, sotalol, The serum concentration of Lidocaine can be increased when it is combined with Sotalol.]
[L01CD04, cabazitaxel, The risk or severity of methemoglobinemia can be increased when Cabazitaxel is combined with Lidocaine.]
[J01FA02, spiramycin, The risk or severity of methemoglobinemia can be increased when Spiramycin is combined with Lidocaine.]
[R03BB01, ipratropium bromide, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
